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Abstract / summary 
Background: Chronic obstructive pulmonary disease (COPD) is a major contributor 
to morbidity and mortality worldwide. Being a preventable disease in most cases, the 
burden on both patients and society may be reduced substantially. Previous research 
on COPD burden has focused on symptoms and treatment costs, while studies on 
working capacity and total societal costs are scarce. Additionally, burden has mainly 
been studied in selective samples from outpatient wards or hospitals, and is not 
representative for a general population. 
The objectives of this PhD thesis were to estimate the worldwide burden of 
unemployment due to COPD, to estimate the incidence and predictors of COPD 
exacerbations, to calculate the costs associated with COPD and its exacerbations, and 
estimate of the productivity loss in Norway. A secondary aim, was to compare our 
estimates in a selected hospital sample to those in a general population sample. 
Methods: For the paper on worldwide unemployment, we used cross-sectional data 
from 18710 participants in 26 sites in the Burden of Obstructive Lung Disease 
(BOLD) study. Odds ratios (ORs) for unemployment associated with chronic airflow 
obstruction (CAO) was estimated with a multilevel mixed-effects generalized linear 
model. For the three other papers, we used the EconCOPD dataset which is a one-
year prospective, observational study including 132 controls and 81 COPD cases 
from a general population, and 205 COPD patients from a hospital-register. 
Multivariable regression models were fitted to find potential adjusted associations 
between predictors and outcome. 
Results: The adjusted odds ratio (95% confidence interval) for unemployment in the 
BOLD study was 1.43 (1.14 – 1.79) for CAO subjects. Age, per 10-year increment, 
and lower education were important risk factors for unemployment in high-income 
sites ((4.02 (3.53–4.57) and 3.86 (2.80–5.30), respectively), while female sex was 
important in low- to middle-income sites (3.23 (2.66–3.91)). In the EconCOPD study, 
the annual incremental productivity losses were 5.8 (1.4 to 10.1) and 330.6 (95% CI 
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327.8 to 333.3) days, comparing population-recruited and hospital-recruited patients 
with COPD to controls, respectively. Further, COPD patients from the population- 
and hospital-based samples experienced on average 0.4 utilization-defined and 2.9 
symptom-defined versus 1.0 and 5.9 annual exacerbations, respectively. The 
incidence rate ratios for utilization-defined AECOPD were 2.45 (95% CI 1.22–4.95), 
3.43 (95% CI 1.59–7.38), and 5.67 (95% CI 2.58–12.48) with Global Initiative on 
Obstructive Lung Disease spirometric stages II, III, and IV, respectively. The average 
annual disease-related costs for a COPD patient from the hospital sample was nearly 
twice as high as for a COPD case from the population sample (€26,518 vs €15,021), 
and nearly four times as high as for a control subject (€6740). The productivity losses 
were substantially higher than the treatment related costs. 
Conclusion: Globally, CAO was associated with significantly increased levels of 
unemployment. In Norway, COPD was associated with a significantly higher 
productivity loss, and higher costs, compared to control subjects. Further on, the 
COPD patients from the hospital sample had a significantly higher burden of 
exacerbations, and higher costs than the COPD cases from the general population. 
Sampling from a general population gives more externally valid results when 




Chronic obstructive pulmonary disease (COPD), is characterised by impaired lung 
function and respiratory symptoms, and overlaps with lung conditions such as 
destructive emphysema and chronic bronchitis. Early observations of emphysema and 
chronic bronchitis can be found from the 18th and 19th century, e.g. by Bonet, 
Morgagni, and Laënnec [1]. This was before tobacco smoking became widespread, 
but after the industrialization had introduced harmful fumes especially exposing 
working class men. Not until the 1950s and -60s, along with an increasing attention to 
the disorder, an attempt was made to define COPD [1].  
COPD is now the third leading cause of death worldwide [2]. Though preventable, 
there is no cure for this chronic disease that affects up to one out of every ten adults 
[3, 4]. In industrialized countries, cigarette smoking is the main cause behind COPD. 
In developing countries, biomass fuel and indoor cooking are additional risk factors 
[5]. Symptoms that are common in COPD include shortness of breath, cough, and 
sputum production [3, 5, 6]. The natural course of COPD varies from patient to 
patient, however in many cases it involves periods of worsening of symptoms, or so 
called exacerbations, with the requirement of additional treatment [3]. These 
exacerbations give rise to higher mortality, reduced quality of life, and increased need 
for health care services, and are a major burden for the patients and to society [7-10]. 
Measuring disease burden can be done with various methods depending on the point 
of view of the researcher. Having the patients in mind, mortality and morbidity, and 
also grading the disability related to the disease, are important aspects. Additionally, 
disease burden can be examined from an economic point of view, making it possible 
to rank the relative economic burden to society of various diseases [11]. 
The purpose of this PhD thesis, was to evaluate the burden of COPD to society, and 
to estimate the incidence of COPD exacerbations from various perspectives. COPD 
affects a substantial proportion of the population, and we wanted to investigate the 
costs of the disease through possible reduced working capacity, both in Norway and 
worldwide. Additionally, we wished to quantify the burden caused by acute 
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exacerbations, and to study potential differences between a general population sample 
and a selected hospital sample. 
 
1.1.1 Chronic obstructive pulmonary disease - definition 
There are several ways to define, or understand, COPD. The most widely used 
definition, is that by The Global Initiative for Chronic Obstructive Lung Disease 
(GOLD), an international collaboration consisting of scientists and clinicians from all 
over the world [12]. In the GOLD “Global Strategy for Prevention, Diagnosis, and 
Management of COPD”, COPD is defined as a chronic, inflammatory disease of the 
airways and/or the lung parenchyma where airways are narrowed, the parenchyma 
may be destructed, and alterations in the pulmonary vasculature may occur [3]. It is 
characterised by irreversible airflow limitation, giving rise to a persistently reduced 
lung function measured by spirometry. Many patients experience dyspnoea, cough, 
and/or overproduction of phlegm, and in most cases the disease is progressive [3, 5]. 
Thus, according to GOLD, performing spirometry is mandatory to diagnose COPD. 
The irreversible expiratory airflow limitation – or chronic airflow obstruction – seen 
in COPD should be reproducible over time, and not reversible upon medication –as 
can be seen in most asthmatic patients (for more details see 1.1.6 COPD – diagnosis, 
and under the Methods section, part 3.3 Spirometry). 
 
1.1.2 COPD – epidemiology 
An early study from 1985 to 1988 found the prevalence of COPD to be around 5% 
[13]. There has been debate around which diagnostic method to use as the estimates 
of prevalence vary substantially according to which definition of obstruction is 
applied [14]. Applying a fixed ratio between the forced expiratory volume in 1 
second (FEV1) and the forced vital capacity (FVC), has been advocated by GOLD 
[15], and has been used worldwide to diagnose obstructive lung diseases. 
Alternatively, an age-adjusted cut-off value for the FEV1/FVC-ratio, where a value 
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below the 5th percentile is considered abnormal, can be utilized, and is referred to as 
the lower limit of normal (LLN). In general, using a fixed ratio for the FEV1/FVC, 
results in higher prevalence estimates than if applying the LLN. It seems that using 
the LLN for diagnosing COPD per spirometry results in more correctly diagnosed 
individuals as there are fewer falsely negative among the younger individuals, and 
fewer falsely positive among the elderly [16-19]. 
 
More recent and larger population studies have found the prevalence of COPD to be 
around 10-11% on an overall, global basis [3, 4], and in Norway it might be as high 
as 14% using the fixed ratio to define COPD [20]. In the general population 
investigated in the Obstructive Lung Disease in Norbotten (OLIN) study, 50% of 
elderly smokers, aged 76 to 77 years old, had developed COPD [21]. 
 
Traditionally, more men have had the diagnosis of COPD, but the last couple of 
decades the sex differences have diminished. Partially, this can be explained by 
increasing consumption of tobacco amongst women, but the association is more 
complex than that, involving different susceptibilities between the genders, and 
furthermore, hormonal and genetic factors may play a role [22-24]. Apart from the 
South-East Asian region, the prevalence of smoking in many low-to-middle-income 
countries (LMIC) is lower than in high income countries, though the gap is narrowing 
[25]. As the health consequences of smoking have become evident, and tobacco 
policies have become more restrictive, most countries see a reduction in tobacco use 
[26]. For instance, in Norway, a reduction in COPD morbidity was seen between 
2001 and 2017 along with decreasing smoking rates [27]. Recent evidence, though, 
show that despite of this, some LMIC experience a rising prevalence of smoking, 
such as the Eastern Mediterranean region and the African region [25]. Scarce 
epidemiological data and less use of spirometry may have led to lower estimates of 
COPD for these regions, and it is expected that the COPD prevalence will rise in 
LMIC the coming years [26, 28]. 
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Worldwide, COPD has become the third most important cause of mortality, claiming 
3.0 million lives in 2016 [2]. 
 
1.1.3 COPD – aetiology 
The aetiology behind COPD is normally an exposure to noxious gases or particles 
over a long period of time. Historically, cigarette smoking has been the main cause, 
but also exposure to biomass fuels, e.g. indoor cooking over open fire, is considered 
an important aetiologic factor [5], as well as workplace exposures [29, 30]. A minor 
group of patients suffer from alpha-1-antitrypsin deficiency that can lead to 
emphysema at young age [31], and additionally, air pollution has been proven to 
increase the prevalence of COPD [32, 33].  
Though several important risk factors have been identified, not all exposed to these 
risk factors end up having COPD [34]. Moreover, some patients seem to suffer from a 
more severe COPD at lower levels of exposure to risk factors. Some proof of a 
genetic predisposition, or host factors, to developing the disease has emerged, 
suggesting there is an interaction between genes and environment behind severe cases 
of COPD [35-37], but the extent or importance of these mechanisms in everyday 
clinical practice is still not clear [38].  
 
1.1.4 COPD – pathophysiology 
The pathologic changes in the respiratory system leading to COPD after years of 
exposure to harmful substances, can mainly be divided into three distinct processes. 
Many patients have alterations in the airways, where chronic inflammation due to 
infiltration of immune cells into the tissue results in hyperplasia of the mucus glands, 
and smooth muscle hypertrophy. Remodelling/fibrosis can also be found. Further on, 
this gives rise to thickening of the airway walls, with limitation of airflow 
(obstruction) and overproduction of sputum [39-41]. A second pathologic change in 
COPD, is the destruction of lung parenchyma, or emphysema. In emphysema, the 
airway walls in the alveoli, beyond the terminal bronchioles, are destructed, and 
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hence, the distal airspace is enlarged, see Figure 1. The elastic recoil force driving air 
out of the lung, is therefore decreased, giving a reduced maximal expiratory airflow 
[42]. Thirdly, the pulmonary vasculature might undergo changes including 
enlargement of the intima and hypertrophy of smooth muscles [39, 43]. Hence, gas 
exchange is impaired, and some patients develop pulmonary hypertension [44]. 
 








1.1.5 COPD – symptoms and comorbidities 
With knowledge of the pathogenesis behind COPD, one can understand the 
characteristic presentation of the patients. Most experience some degree of dyspnoea, 
cough, and/or sputum production on a daily basis [3]. 
One important feature of COPD is the presence of comorbid conditions [45]. The 
most severe and frequent comorbidities in COPD are, amongst others, cardiovascular 
disease, lung cancer, anxiety and depression, osteoporosis, diabetes, obesity, and 
gastroesophageal reflux disease (GERD) [46]. Comorbidities have been shown to 
decrease the quality of life, to have an association with increased rates of 
exacerbations, and to increase the mortality in COPD [45, 47, 48]. 
There is significant overlap of the symptoms and of how COPD patients present, but 
to some extent one can distinguish certain phenotypes of COPD. A phenotype can be 
defined as the observable traits or characteristics of an organism. The two traditional 
COPD phenotypes included the emphysematous patient suffering from dyspnoea. 
Often underweight, with barrel chest, tachypnoea, and a slightly reddened face, this 
phenotype became known as the pink puffer. The second traditional phenotype was 
the blue bloater, an overweight, hypoxaemic patient with symptoms of chronic 
bronchitis such as cough and overproduction of sputum [49]. Both brilliantly 
portrayed by Frank Netter (Figure 2a and Figure 2b). As the appreciation of the 
complexity and heterogeneity of COPD has grown, so has the perception of 
phenotypes. In clinical work, you might meet the occasional “pink puffer” or “blue 
bloater”. But more often, the patients do not fit into either of these two described 
phenotypes. It is now widely acknowledged that one size do not fit all when it comes 
to chronic airway diseases, and that we need to move towards a more 
multidisciplinary approach. The term treatable traits, has been put forward, where the 
search for specific biological pathways, or endotypes, that can explain the observable 
phenotype, is important. Emphasising such individual patient presentation, and 
offering a multidimensional management, has been shown to improve the patients` 





The Pink Puffer, by 
Frank Netter. 





Netter illustration used 
with permission of 




The Blue Bloater, by 
Frank Netter. 
Characterized by a 
cyanotic, overweight 




Netter illustration used 
with permission of 




1.1.6 COPD - diagnosis 
The diagnosis of COPD should be made on the basis of symptoms suggestive of the 
disease combined with proof of airflow obstruction per spirometry that is not 
reversible after administration of a bronchodilator, and that is reproducible over time 
[3, 6]. A reduced FEV1/FVC-ratio indicates airflow obstruction, either defined by a 
fixed value of 0.7, or by the lower limit of normal. 
GOLD has during the years advocated various tools to grade disease severity of 
COPD. Reduction in FEV1 is used to grade COPD either as mild (FEV1 > 80% of 
predicted), moderate (FEV1 50-80% of predicted), severe (FEV1 30-50% of 
predicted), or very severe (FEV1 < 30% of predicted), also known as GOLD-stages 1-
4 respectively [51]. More recently, the GOLD group suggested a more complex 
system of grading the disease using both dyspnoea score, and exacerbation history, in 
an attempt to make more personalised decisions on treatment. This is known as the 
ABCD assessment tool [52].  
In most cases, there is an anamnestic history of significant exposure to pneumotoxic 
substances (normally cigarette smoking, or exposure to occupational dust), or a 
family history of chronic pulmonary disease. The clinical presentation can include 
dyspnoea, wheezing, cough or repeated bronchitis, and/or overproduction of sputum, 
though some present with the incidence of a comorbid condition [3, 6, 39].   
Previous studies have also shown that COPD is massively underdiagnosed. In the 
Burden of Obstructive Lund Disease (BOLD) study, more than 80% of subjects with 
chronic airway obstruction were not aware of this [53]. This might of course be 
related to variation in the access to healthcare services, but also to systematic 
underreporting of airway symptoms. A failure to report symptoms of COPD has been 
associated both with a stigma related to having COPD, and with the sedentary 
lifestyle many affected individuals adopt [54, 55]. On this background, it is 
recommended that anyone above 40 years of age who present with symptoms 
suggestive of COPD should undergo spirometry, especially if they have a history of 
smoking or other relevant exposures [3, 5, 6].  
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1.1.7 COPD – exacerbations 
The course of COPD involves periods of exacerbation of symptoms in between more 
stable periods [3, 6]. Such exacerbations are responsible for a temporarily increased 
need for treatment or even hospitalisation of the patients. Some patients experience 
frequent exacerbations, whilst others seem to avoid such exacerbations completely 
[56]. These acute exacerbations of COPD (AECOPD) often have an infectious cause 
and are associated with a more rapid decline in lung function, increased use of 
healthcare resources, and increased mortality compared to COPD patients without 
frequent exacerbations [7-10, 57-59]. Previous literature has shown a varying rate of 
exacerbations amongst COPD patients. Some studies have provided an estimate of 
less than one exacerbation per patient per year [60, 61], whilst other studies have 
shown the exacerbation rate to be between two and three per patient per year [7, 62]. 
These previous studies used different sample sources, and they differed in how they 
defined an AECOPD. In general, population-based studies found lower rates of 
exacerbations [60, 61, 63] than those targeting more selected populations, i.e. 
outpatient clinics or hospital registers [7, 62, 64]. In addition, more permissive 
definitions of an exacerbation resulted in higher exacerbation rates than more strict 
definitions. E.g., in the Hokkaido sample studied by Suzuki et al., the rate of 
exacerbations was 0.78 per patient per year when defining an exacerbation as a 
subjective complaint of symptoms, whilst only 0.06 per patient per year when 
defining an exacerbation as the need of hospitalisation due to respiratory symptoms 
[65]. 
 
Predictors of exacerbations have been examined in various studies [56, 60, 64-71], 
and it has repeatedly been seen that both higher age [64, 66, 67], increasing airflow 
obstruction [56, 60, 68], a history of previous exacerbations [56, 64, 68], 
inflammatory biomarkers [69, 70], gastroesophageal reflux disease [71], and reduced 
quality of life [65, 67, 68] all increase the risk of exacerbation. But again, the results 




All in all, previous studies vary substantially in their methodology, and are difficult to 
compare. Very few have samples from general populations [60, 68]. When 
undertaking this PhD project, the effect of sampling source and exacerbation 
definitions on the results had not been studied in adequate circumstances. We wanted 
to investigate how the exacerbation rate potentially could differ between a general 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.1.8 COPD – treatment and prevention 
As with love [72], “there ain`t no cure” for COPD. First and foremost, the best way to 
preserve lung health and avoid COPD is to avoid smoking. Restrictive tobacco 
policies are one of the most effective measures to maintain a good public (lung) 
health [73]. Both increased smoking cessation rates and reduced smoking initiation 
have been attributed to tobacco-control programmes [74, 75]. Increased taxes on 
tobacco have been identified as the most effective intervention against non-
communicable diseases and the expected millions of premature deaths attributed to 
tobacco-use in the decades to come [76, 77].  
 
All COPD patients should be recommended to quit if still smoking [3, 5, 6]. In 
sustained quitters, the Lung Health Study showed a slower decline in lung function, 
less need of hospitalisation, and a lower all-cause mortality rate [78]. Secondly, 
pulmonary rehabilitation has been proven effective in improving health-related 
quality of life, tolerance to exercise, and reducing the need for health care services 
[79]. A study by Maddocks et al showed that even fragile COPD patients could have 
great benefit from pulmonary rehabilitation, improving both dyspnoea, physical 
activity, and overall health status [80]. The third most important intervention is 
vaccination, both against seasonal influenza, and pneumococcal disease. In two 
separate Cochrane reviews, it was found that influenza vaccination was significantly 
associated with a reduced exacerbation rate [81], and that pneumococcal vaccination 
protected against community-acquired pneumonia [82]. Further on, there has been 
seen an additive effect of receiving these two vaccines together [83]. 
 
The medication available consists mainly of inhalation drugs that can alleviate 
symptoms, and to some degree reduce the exacerbation rate and need for 
hospitalisation [84, 85]. It is recommended that all COPD patients that are 
symptomatic try out either rescue medication (if intermittent symptoms) or 
maintenance therapy (if persistent symptoms). The effect of rescue medication is 
rapid, but short-lasting. The most widely used drug for rescue medication is the ß-
agonist salbutamol with nearly 300.000 users in Norway [86], but also the short-
 32 
acting anticholinergic drug ipratropiumbromid has quite a wide use. Maintenance 
therapy should include some form of long-acting medication, either a LABA (long-
acting ß-agonist), or a LAMA (long-acting muscarinic antagonist) [3, 5, 6], or a 
combination of the two. ICS (inhaled corticosteroids) have been used widely, but 
have an association with increased rates of pneumonia. Hence, ICS should be 
preserved for those experiencing frequent exacerbations where a somewhat reduced 
rate of serious events has been seen [84], or for patients with eosinophilia where 
recent evidence suggests a benefit [87]. Additionally, there can be a slight positive 
effect on inflammation adding the systematic PD4-inhibitor roflumilast in severe 
cases of COPD [88]. End-stage COPD may result in respiratory failure with 
hypoxaemia and/or hypercapnia, and some patients may profit from long-term 
oxygen treatment (LTOT). When exacerbating, patients often need systemic 
corticosteroids, and in many cases antibiotics. Patient education should enable 
patients to increase the rescue medication as appropriate when experiencing a 
worsening. If severe, exacerbations may lead to hospitalisation, and in some cases 
even intubation and treatment in intensive care units [3, 5, 6]. 
 
1.1.9 COPD – burden and prognosis 
In the 1990s, there was a lack of comparable studies on burden of disease, and the 
World Health Organisation (WHO) together with the World Bank pushed forward an 
initiative resulting in the Global Burden of Disease (GBD) Study [89]. This study 
used comprehensive and consistent methods to achieve comparable information on 
causes of disease and how global health changes over time. From the GBD, Murray et 
al found that COPD ranged second on the list of causes of disability-adjusted life-
years (DALYs) [90], confirming how debilitating the disease is. Additionally, it was 
found that the burden attributable to tobacco smoking remained constant from 1990 
to 2010 at 6.3% of all the DALYs in the world [90]. Whilst utmost descriptive, the 
GBD Study does not give an economic evaluation of the societal costs associated 
with each disease in monetary units, nor does it examine what drives the costs. 
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The individual burden of COPD is influenced by many factors. For instance, the 
mental and physical capability to face daily symptoms, and personal economy to pay 
for treatment or to be able to be absent from work, can all affect how the patients 
experience their disease. In general, COPD symptoms are associated with a reduced 
quality of life, but also with higher incidence of comorbid depression and anxiety, 
reduced sleep quality, and with worse disease prognosis [91]. In some cases, be it a 
genetical predisposition or in those who cannot manage to stop smoking in time, the 
condition can become very severe and give a heavy burden on the individual 
promptly [92, 93]. In most cases though, the disease progresses slowly [94], and can 
be delayed with effective means such as smoking cessation and pulmonary 
rehabilitation [73, 78, 95]. In smokers at 65 years of age with GOLD-stage 3 to 4 
COPD, it has been estimated that nearly 10 years of life expectancy is lost due to 
COPD and continued smoking. On the other hand, COPD in never-smokers is 
associated with a reduction in life expectancy of 1.3 years in GOLD-stage 3 to 4 [96].  
 
1.2.1 Health economics 
The science of economy, or economics, concerns the production, distribution, and 
consumption of activities that aid in determining how scarce resources should be 
allocated to fulfil the needs of those living within each economy [97]. 
As a part of the larger area socioeconomics, health economics deals with how the 
resources of the society can be best used to gain most health in a population. The 
available resources are not infinite, and hence, what can be spent on health in any 
society, has a limit. It is stated that the aims of the Norwegian health politics, are to 
“gain more life years of good health in the entire population”, that “every citizen 
should have equal access to help for equal needs”, and to “reduce the social 
inequality in health” [98]. To obtain these aims with limited resources, one is obliged 
to prioritise. How to prioritise fairly is inevitably a question where personal opinion, 
or political conviction, may play a role, but some help can be found in moral theory 
that guide decision making and evaluate the morality of actions and public policies 
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[99]. Further on, prioritising fairly can more easily be done when real cost estimates 
for the different conditions exist, facilitating the evaluation of each condition relative 
to one and another. 
Costs in health economy can include many items, for instance patient expenditures on 
medication, the cost of an appointment with a GP or at an outpatient clinic, the time 
spent by relatives on care of a patient, or the costs to society associated with sick 
leave or disability to work. The definition of a cost in economics is the value of 
opportunity forgone as a result of spending resources in an activity, also known as the 
opportunity cost [100]. In other words, regarding health, a cost is the forgone 
opportunity to spend that amount of money in a different manner had it not been 
spent on the disease in question.  
Many studies use attributable costs to give estimates of how much costs a disease is 
responsible for. With this approach, the costs explicitly related to the treatment of the 
index disease are estimated and can allow us to calculate the percentage of the total 
medical costs that are attributable to the index disease. In contrast, the excessive costs 
(also called the incremental costs or marginal costs), are the costs in a sample with 
the index disease compared to the costs in a population without the index disease, a 
control group. With good matching of the controls for confounding factors, such as 
age, gender and education, the incremental cost approach can give more accurate 
results than the attributable cost approach [101]. 
 
1.2.2 Health economics - cost-of-illness studies 
Cost-of-illness (COI) is defined as the value of the resources that are expended or 
forgone as the result of a health problem. It encompasses costs related to health care 
utilization (direct costs), costs due to absenteeism from work or lost productivity 
(indirect costs), and costs related to suffering and pain (intangible costs) [102, 103]. 
There are several methods of how to undertake COI studies, but the common 
underlying assumption has traditionally been that such an economic study represents 
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the potential benefits of a health care programme (or treatment, or intervention) had it 
eradicated the illness [104]. 
The direct costs, or treatment-related costs, consist of healthcare costs and non-
healthcare costs. The healthcare costs are those that arise from use of medication, 
treatment sessions or consultations with any health care personnel, admission to 
hospital, or any cost related to the diagnosis, treatment, rehabilitation, or terminal 
care of a disease. The non-healthcare costs are those incurred by transportation to and 
from providers of care, informal care e.g. by family members, or costs due to 
relocation or legal help [103].  
The direct costs can be estimated in a bottom-up, or a top-down manner. In the 
bottom-up manner, each expenditure, or unit, has its related cost, the unit cost. Each 
unit cost is multiplied by how many times the unit was used, for example how many 
GP consultations a patient had per year. Finally, all unit costs are summed up to give 
the total direct costs, for instance per patient per year. On the other hand, the top-
down approach starts in the other end, taking the total national health care 
expenditure and dividing this total sum on each disease category in the ICD-10 
system. 
Apart from the top-down or bottom-up approach to estimate the direct costs, COI 
studies can be described depending on the epidemiological data used, i.e. an approach 
based on either prevalence or incidence. With a prevalence based method, the 
economic burden of a disease is calculated for a specific time period, most often a 
year. Using an incidence based approach, patients are included when they get the 
disease (or when the disease is diagnosed), and can give rise to costs as long as they 
have the disease, i.e. the lifetime costs of the disease in interest are estimated. [104]. 
For long-lasting diseases, the incidence based approach might not be feasible due to 
the follow-up time being too far into the future, and the prevalence based method 
might be the only way to perform such studies. In general, incidence based COI 
studies result in higher costs than the prevalence based studies due to the fact that 
future costs are summed up with the incidence based method, while with the 
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prevalence based method the costs are assigned to the year when the disease appears 
and future expenditure is discounted. Especially for chronic and long-lasting diseases, 
the differences in cost results between using a prevalence and an incidence based 
method could be substantial [103]. Finally, COI studies can be performed either 
collecting data prospectively, or retrospectively. Briefly, a retrospective study design 
is less expensive and less time consuming to perform compared to a prospective 
design. Though, with a prospective design assigning costs can be more accurately 
done, e.g. using diaries during the study period. 
The productivity losses, or indirect costs, are the costs related to absenteeism from 
work or to the disability to participate in the workforce and can be estimated mainly 
in 3 different ways. So far, there is no consensus on which method is the best. The 
human capital approach (HCA) forms the theoretical background for estimating 
productivity losses due to morbidity and mortality [103]. In the 1950s and `60s, 
economists began having interest for human resources as a neglected part of the 
economy, and hence, good health was also seen as an investment to society [105]. 
The HCA was further developed from its origin to express the value of human labour. 
It states that the future earnings of an individual are equal to its potential value to the 
economy. Average wages are used to put monetary value on each individual´s 
contribution, using the assumption that the wage of a worker is equal to his/her 
marginal product. The marginal product being defined as the change in total output as 
one additional unit of input is added to production [11]. The HCA fits best in 
societies with full employment, or at least with a low unemployment rate, which has 
led to an alternative method to perform COI studies – the friction cost method 
(FCM). 
In the FCM, it is argued that if a person is sick or dies prematurely, and therefore 
cannot work or only work partially, he/she is eventually replaced from the pool of 
unemployed individuals [103]. In contrast to the HCA, in the FCM there is only a 
period of reduced or lost productivity, the friction period, until the sick/deceased is 
replaced, and normal productivity is achieved again. I.e., it is the friction period that 
needs to be calculated to put a value on the lost productivity [103]. The length of this 
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period depends upon the availability of qualified personnel, and upon unemployment 
rates. 
Both the HCA and the FCM have been criticised by economists saying that wages 
have nothing to do with how much should be spent on saving someone`s life. It has 
been argued that a third approach should be used, namely the willingness-to-pay 
(WTP) approach. With the WTP method, each individual is asked to put a monetary 
value on how much they would spend to reduce the risk of disease, and this value is 
considered the real cost of disease. It seems that doing so, those asked imagine all 
kinds of effects a reduction in health risk may have on their lives, and even intangible 
costs may be covered for with the WTP method [106]. However, the WTP method 
does not consider that people have different fortunes and salaries, so that the 
willingness to pay does not necessarily reflect the ability to pay. 
Macroeconomic issues, or the economy as a whole in each country, will inevitably 
affect which method for performing COI studies that is most appropriate in each case. 
Some countries have in majority a public health care system, others have a majority 
of private health care, and many economies offer a combined health care system to its 
inhabitants. Hence, the amount paid by the authorities and by the patients themselves, 
vary hugely from country to country. Based on such differences, each researcher must 
choose what is most suitable for his/her circumstances, and this makes the field of 
health economy even more difficult to unite and compare. Elucidating 
methodological details is the minimum requirement to facilitate the comprehension of 
what perspective research has been conducted under, and to evaluate if separate 
studies are comparable or not. 
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Cost-of-illness studies have been criticised for squandering with research resources, 
and that the monetary costs of disease are irrelevant if not reported together with a 
potential benefit of preventing or treating the disease in question. It has been argued 
that there is already meaningful information available to describe the cost of illness, 
i.e. data on mortality or hospital admissions, and that no further estimation of the 
costs is necessary as these data already quantifies the problem in an adequate manner 
[107]. On the other hand, when there is a known prevention strategy available that 
can prevent the occurrence of an illness, cost-of-illness studies are useful. For a 
preventable disease such as COPD, COI studies can be used as an estimate of the 
opportunity cost forgone if prevention is not accomplished. Additionally, preventing 
smoking would not only affect rates of COPD, but also many other diseases with a 
high burden, such as cancer and cardiovascular disease. Hence, COI studies on 
COPD give a very conservative estimate of possible savings in the health budgets. In 
other words, COI studies should not be used to say which of a set of illnesses is 
worst, but to give an order of magnitude to the opportunity cost that is forgone if the 
disease is not prevented [102, 103, 107]. 
 
1.2.3 Health economics - costs of COPD 
Being defined as a preventable disease [3, 5, 6], great reduction of both personal and 
socioeconomic burden from COPD is within reach. The actual monetary cost of 
COPD and AECOPD to society has been investigated in a few studies [108-112]. In 
the OLIN study, Jansson et al found the average annual direct costs to range from € 
269 to € 5,351 for mild and very severe cases, respectively [112]. In the same study, 
the indirect costs ranged from € 327 to € 12,004 for mild to very severe disease, 
respectively. Using the same population sample, Andersson et al found that severe 
exacerbations were 10 times more costly than moderate exacerbations, and that 
hospitalisation costs accounted for two thirds of the total exacerbation cost [110]. A 
study by Dalal et al, found that per simple COPD admission to hospital the cost was 
USD 7,242, and per complex admission due to COPD the cost was USD 20,757 
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[111]. In a study by AbuDagga et al, the mean cost per moderate exacerbation was 
USD 269, whilst the cost per severe exacerbation was USD 18,120 [108]. Each 
additional exacerbation was associated with 9.1% higher exacerbation costs in the 
follow-up year. Miravitlles et al found a mean cost per exacerbation of € 345, of 
which costs related to hospital care constituted 73% [109]. 
 
It is clear that COPD is a costly disease. Investigating both treatment-related costs 
and productivity losses in a general population using a prospective approach has to 
our knowledge only been done on the OLIN sample, and neither did they have a 
control sample enabling estimation of the incremental costs, nor did they evaluate the 
productivity losses due to exacerbations. For a fairer distribution of resources, having 
a population-based estimate on total costs of disease, and knowing what the main cost 
drivers are, is essential. To give such an estimate for the long-lasting and chronic 
disease COPD, we argue that not only should the study sample be from a general 
population, the design also ought to be prospective with a bottom-up approach 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2 Objectives of the thesis 
1) To estimate and compare the employment status in BOLD-participants with and 
without chronic airway obstruction across the world. 
2) To estimate the productivity losses associated with COPD in Norway, to compare 
the results from a general population to that of a hospital sample, and to 
investigate possible predictors of productivity losses in COPD. 
3) To estimate the incidence and examine potential predictors of acute exacerbations 
of COPD in a general population, and to compare the results to a hospital sample. 
Do the results differ if an exacerbation is defined by symptom-worsening 
compared to a definition based on resource use? 
4) To estimate the annual socioeconomic costs related to COPD and COPD 
exacerbations, evaluate predictors of increased costs, and to compare the results 










3 Material and methods 
This thesis builds upon two distinct datasets, one from the Burden of Obstructive 
Lung Disease (BOLD) study, and one from the Economics of COPD (EconCOPD) 
study. The Norwegian site in the BOLD study, and the EconCOPD study, both 
recruited from the 2003-2005 follow-up of the Hordaland County Respiratory Health 
Survey (HCRHS). Details on sampling and design of the HCRHS are previously 
published [13]. Shortly, the HCRHS is a cohort study based on a random sample of 
the adult population between 15 and 70 years of age in Hordaland County in 1985, 
with three follow-ups (in 1987-88, 1996-97, and in 2003-05), see Figure 3. In 2005, 
there were a total of 1717 responders who were eligible for invitation to the 
EconCOPD study. For the BOLD study, the same 1717 were eligible for inclusion, 
together with 755 HCRHS non-responders. Figures 4 and 5 show the flow charts for 
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Figure 4; Flow chart for the EconCOPD survey. Cases and patients had COPD defined as FEV1/FVC 
<0.7 and FEV1 <80% of predicted. Controls had FEV1/FVC >0.7 and FEV1 >80% of predicted. All 
participants were ≥ 40 yrs and had at least smoked the equivalent of 2.5 packyears. Figure reprinted 






Figure 5: Flow chart for the Norwegian site of the BOLD survey. Figure reprinted with permission from Rune 




3.1  Study population and design 
 
3.1.1 The BOLD Study 
The BOLD study is an international, multicentre, cross-sectional study that collected 
data for over 30.000 persons in 42 sites when completed. The BOLD protocol has 
previously been published [114]. Briefly, the BOLD study was designed as a 
prevalence study of COPD amongst non-institutionalised adults of 40 years or more. 
The primary aims of the BOLD initiative is to 1) measure the prevalence of COPD 
and its risk factors in various areas of the world; 2) estimate the burden of COPD in 
terms of impact on quality of life, activity limitation, respiratory symptoms, and use 
of health care services; and 3) develop a model to project future burden of disease for 
COPD.  
 
In Norway, Bergen was the only participating site. Haukeland University Hospital 
(HUH), and the Institute of Medicine, University of Bergen, cooperated in the study, 
and recruited responders and non-responders from the follow-up of the HCRHS, see 
Figure 4. At the time of invitation, the eligible invitees had an age-range of 35 to 90 
years old, but only those 40 years or older were invited. All non-responders (N=409) 
from the third follow-up of the HCRHS in 2003-05 who had not moved or died 
(N=346) were invited. A random 70% of 1010 responders 40 years or older were also 
invited. Of these 1130 possible participants, 1044 were eligible for full participation. 
386 of these ended up as non-responders (see Figure 5), and 658 were full responders 
forming the final BOLD sample for Bergen. All participants were either seen at the 
outpatient clinic, or in their homes by an investigator. Questionnaires were answered, 
and a post-bronchodilator spirometry was performed. The study co-workers were all 
trained and certified by BOLD coordinating centres to obtain the highest quality 
possible for the gathered data and for the performance of spirometry. 
 
When undertaking the analysis for paper I, the BOLD study had completed the data 
collection in 26 sites around the world (Figure 6). In total, 22118 participants had 
provided interview data, of which 18710 performed a satisfactory post-bronchodilator 
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spirometry and were included in the analysis. However, when analysing the outcome, 
risk of unemployment, all participants above 65 years of age (defined as retirees) and 
homemakers/caregivers were excluded. After this exclusion, there were no cases with 
chronic airflow obstruction (CAO) left in Tirana, Albania, hence this site was not 
included in the analyses of the effect of CAO on unemployment risk. Sampling 


































































3.1.2 The EconCOPD study 
The EconCOPD study was a prospective COI-study of a Norwegian general 
population with one year of follow-up. It was conducted between March 2005 
and August 2006 at the Department of Thoracic Medicine, Haukeland 
University Hospital, Bergen, Norway. The study sample was made up of three 
different groups of participants; COPD cases from the general population, 
control subjects from the same general population, and hospital recruited 
COPD patients. All participants were at least 40 years old when invited, and 
had smoked a minimum of 2.5 pack years of cigarettes – 1 pack year being 
defined as smoking 20 cigarettes daily for one year. 
 
Both the population-based controls and COPD cases were recruited based on 
age, smoking habits, and spirometry from the 2003-05 follow-up of the 
HCRHS. The hospital-based COPD patients were recruited from the COPD 
register of HUH between September 1997 and December 2004. ICD-10 codes 
J41-J44 (emphysema, chronic bronchitis, and COPD) and J96 (respiratory 
failure) were used to identify potential subjects for inclusion in the study. A 
few subjects were present both in the HCRHS and in the hospital register. To 
avoid including them in both samples, they were kept in the HCRHS-
population, and deleted from the hospital register. 
 
Both the population-based COPD cases and the hospital-recruited COPD 
patients had spirometry defined COPD of GOLD-stage II–IV with a post-
bronchodilator FEV1/FVC-ratio of less than 0.7, and an FEV1 of less than 80% 
of predicted. The control subjects had an FEV1/FVC-ratio above 0.7, and FEV1 
of at least 80% of predicted. 
 
Initially, an invitation letter was sent out to all eligible participants who were 
contacted by telephone after receiving the letter. Those interested in 
participating were given an appointment at the outpatient clinic at the 
Department of Thoracic Medicine, HUH. During this appointment, they first 
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received study information, and then signed the informed consent form, before 
they went on with a face-to-face interview. This baseline interview gathered 
information on demographic variables including educational level, smoking 
habits, diagnoses, comorbidities and drug utilization. After inclusion, the 
participants were followed for one year with telephone interviews at 12 weeks, 
24 weeks, 36 weeks, and 52 weeks after the baseline interview. The follow-up 
interviews by telephone covered information regarding utilization of health 
care services and respiratory symptoms since last interview, and also if there 
had been any change in working life participation due to sick leave or disability 
pension. All questionnaires and the consent form are attached in the Appendix. 
Figure 4 shows the details of the inclusion and causes of non-response for the 
whole study period. 
 
3.1.3 Ethics 
Both the BOLD study and the EconCOPD study included only volunteers that 
had provided written consent to participate. The BOLD protocol was written in 
accordance with the Helsinki declaration, and was approved by ethics 
committees at all local sites. In the Norwegian site, the Regional Committee for 
Medical and Health Research Ethics in Western Norway (REK Vest) approved 
the study (approval REK Vest case no. 098.05). The EconCOPD study was 
also approved by REK Vest before study start (REK Vest case no. 252.04). 
 
 
3.2 Questionnaires and exposures 
All questionnaires used in this thesis, both for the BOLD study and the 
EconCOPD study, are presented in the Appendix. 
3.2.1 The BOLD study (Paper I – Unemployment in chronic airflow 
obstruction) 
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The BOLD core questionnaire was asked to all participants by study co-
workers, in a structured face-to-face interview in each site. The questionnaire 
gathered information on smoking habits, education, living standards, job status, 
self-reported comorbidities (hypertension, heart disease, diabetes, stroke, and 
lung cancer), respiratory symptoms (dyspnoea, wheezing, and chronic 
bronchitis), and exacerbations of respiratory symptoms. Previously validated 
instruments, as the 1978 ATS/DLD Respiratory Symptom Questionnaire [115], 
the European Community Respiratory Health Study screening questionnaire 
[116], and the US Lung Health Study questionnaire [117], were used when 
possible. Smoking status was divided into never-smokers (subjects who had 
smoked < 20 packs of cigarettes in their lifetime), ex-smokers (subjects who 
reported an age at which they had stopped smoking), and current smokers. The 
highest level of completed schooling defined the participant`s educational level 
(either no schooling, primary school, middle school, high school, some college, 
or completed college/university education). Dyspnoea was defined according to 
the modified Medical Research Council (mMRC) questions, and graded from 0 
to 4 [118]. Wheezing was defined as attacks of wheezing associated with 
dyspnoea in the last 12 months, while chronic bronchitis was defined as 
productive cough on most days at least three months per year for at least two 
consecutive years. 
 
3.2.2 The EconCOPD study (Papers II, III, and IV) 
Before the main EconCOPD study, a pilot survey was performed [119]. Based 
on this pilot survey, the questionnaires for the main study were developed and 
named “the Norwegian Cost of COPD baseline Questionnaire (NCCQ-b)”, and 
“the Norwegian Cost of COPD follow-up Questionnaire (NCCQ-f)”. The most 
important change from the pilot survey, was that instead of asking for costs 
specifically due to respiratory disease (for calculating attributable costs), the 
final questionnaire asked for all health care utilization independent of disease. 
This enabled the calculation of excessive costs, in which you need access to 
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health care utilization irrespective of which condition triggers the requirement 
of health care services. 
 
All papers from the EconCOPD study used the same definition of smoking 
status and educational level. Smoking status was divided into current smoking, 
or former smoking if the participant gave a date or year for having quit 
smoking. In some statistical models, we examined smoking exposure using the 
number of packyears smoked (one packyear being equivalent of smoking 20 
cigarettes per day during one year). Educational level was divided into three 
levels: primary school, secondary school, and university. Further, the Charlson 
Comorbidity Index was used to gather information of comorbidities [120]. For 
questions regarding health care utilization, we modified a questionnaire from a 
Swedish study on the burden of COPD, the OLIN study [121]. Severity of 
COPD was defined using the GOLD stages II, III, and IV. All stages had an 
obstructive post-bronchodilator FEV1/FVC-ratio of less than 0.7. GOLD stage 
II had in addition an FEV1 between 50 and 80% of predicted, stage III between 
30 and 50% of predicted, and stage IV < 30% of predicted. 
 
3.2.3 Paper II – Productivity losses in chronic obstructive pulmonary disease 
In the paper on productivity losses in COPD, both the baseline and the follow-
up questionnaires were used. An exacerbation of respiratory symptoms was 
defined according to the modified Anthonisen criteria [122] as an increase in 
two major symptoms (dyspnoea, sputum volume, or sputum colour), or one 
major and one minor symptom (cough, sore throat, nasal secretion, wheezing, 
or asthenia) for at least two consecutive days. Both the hospital-recruited 
COPD patients, the population-dwelling COPD cases, and the population 
controls were asked about symptoms of respiratory exacerbation. With this 
approach, we were able to quantify the occurrence of exacerbation-like events 




3.2.4 Paper III – Incidence of COPD exacerbations 
In this paper, only the four follow-up questionnaires were used to calculate the 
annual cumulative incidence of acute exacerbations of COPD (AECOPD). To 
evaluate the potential differences in the incidence of utilization-defined and 
symptom-defined exacerbations, we used two distinct definitions of an 
AECOPD in this paper, see Section 3.5 Outcome variables. Adjustment was 
made for several demographic variables (sex, age, education, and smoking 
habits), and further adjustment for other potential predictors (comorbidities, 
severity of COPD, maintenance therapy, and BMI) was made. Maintenance 
therapy was defined as regular use of long-acting muscarinic antagonists, long-
acting beta-2 agonists, inhaled corticosteroids, or theophylline. BMI was 
defined as the weight of the participant in kilograms divided by their squared 
height measured in meters. Smoking status was divided into current or ex-
smokers. 
 
3.2.5 Paper IV – Incremental costs of COPD and COPD exacerbations 
In this paper, we evaluated the annual costs associated with COPD, both in the 
hospital-recruited COPD patients, and in the population-dwelling COPD cases. 
We used the four follow-up questionnaires to cover for a whole year. We used 
the utilization-based definition of an exacerbation, and the exacerbations were 
divided into moderate or severe. The moderate exacerbations were those 
requiring antibiotics or corticosteroids, whilst the severe exacerbations were 
those requiring hospitalization. COPD severity was defined according to 
GOLD-stages II – IV (GOLD-stage II defined by FEV1 50-80% of predicted, 
GOLD-stage III by FEV1 30-50% of predicted, and GOLD-stage IV by FEV1 < 
30% of predicted). 
 
3.3 Spirometry 
Spirometry is a pulmonary function test (PFT) that measures the volumes of air 
a person inhales and exhales as a function of time [123]. It is valuable as a 
screening test for general respiratory health, and if used together with 
 55 
information on symptoms or exposures to lung toxic agents, it can be used 
diagnostic in many circumstances. Performing a spirometry involves maximum 
inhalation followed by a forceful exhalation where the subjects are asked to 
exhale as rapidly and forcefully as possible until the airflow stops. The 
spirometer registers the volume of air exhaled as time passes. The most 
important measurements are the forced vital capacity (FVC), the forced 
expiratory volume in one second (FEV1), and their ratio (FEV1/FVC). 
 
3.3.1 The BOLD study 
In the BOLD study, a portable ndd EasyOne® Spirometer (ndd Medizintechnik 
AG, Zürich, Switzerland) was used. All BOLD technicians went through 
certification, and all spirometer manoeuvres were evaluated at the BOLD study 
pulmonary function reading centre [114]. The spirometry was performed 
before and after bronchodilation with 200 µg salbutamol through a large-
volume spacer. Spirometry was performed according to American Thoracic 
Society standards [124]. Equations for Caucasians from the third National 
Health and Nutrition Examination Survey (NHANES-III) were used to estimate 
predicted values for FEV1, FVC, and the FEV1/FVC-ratio according to the 
subjects` age, height, and sex. Spirometric CAO was defined as a post-
bronchodilator FEV1/FVC-ratio below lower limit of normal (LLN). 
 
3.3.2 The EconCOPD study 
In the EconCOPD study, the spirometry results from the 2003-05 follow-up in 
the HCRHS and from the 2003-05 investigation of the HUH COPD patients 
were used. Spirometry was performed 30 minutes after inhalation of 400 µg 
salbutamol through a large-volume spacer, and all measurements were done 
according to ATS standards [124]. A Vitalograph 2160 spirometer 
(Vitalograpgh Ltd, Maids Moreton, UK) was applied. Predicted values were 
calculated using a pre-bronchodilator reference equation based on the HCRHS 
population [125]. COPD was defined by a fixed ratio of FEV1/FVC < 0.7, post-
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bronchodilator. Grade of airflow obstruction, i.e. disease severity, was 
classified according to the GOLD-stages by FEV1 in % of predicted [3]. 
 
3.4 Data management and quality control 
The data management and quality control for both the HCRHS and the BOLD 
study have been published previously [4, 113, 114, 126] and is briefly 
described hereunder. 
 
3.4.1 The BOLD study 
The BOLD Operations Centre (OC) provided overall administration and 
supervision of the whole study initiative. Initially, the OC was situated at the 
Kaiser Permanente Center for Health Research in Portland, Oregon. The OC 
had the responsibility of supervising all aspects of the protocols for each site. 
The study incorporated meticulous quality control into the methods to secure 
reproducibility. All spirograms were reviewed by the pulmonary function 
reading centre, initially located in Salt Lake City, Utah. Only spirometry results 
that fully met the ATS acceptability criteria and were reproducible to within 
200 mL were included in the study. Both the OC and the pulmonary function 
reading centre were later joint in the coordinating centre at the National Heart 
and Lung Institute, Imperial College London, UK. Data collection and 
transferring of data from questionnaires was standardised, and once completed 
for any given site, the OC provided the site with an electronic copy of its own 
cleaned and edited data set. The OC retained a copy of the data sets for all sites 
for pooled, cross-site analyses. 
 
Before data collection, all study staff was trained and certified in study 
procedures. There are formal written procedures for all aspects of the study, 
including the questionnaire, lung function testing, data management, and study 
sample collection. The questionnaires were both translated into the local 
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language at each site, and back-translated into English by the OC to check for 
incongruences between the original and the back-translated version [4, 114]. 
 
3.4.2 The EconCOPD study 
Four medical students, one project nurse, and the project physician performed 
the baseline visits. All interviewers performing the baseline interview had 
attended a seminar presenting the protocol and a lecture on COPD. They 
practiced interviewing technique by participating in role play, and by 
interviewing symptomatic COPD patients admitted to the Department of 
Thoracic Medicine, HUH. The project physician, Rune Nielsen, observed the 
interviews at the inward. Additionally, all interviewers watched one complete 
baseline visit held by the project physician. All questionnaires were checked 
and corrected for errors, inconsistencies, and missing values by the project 
physician or the project nurse. Using SPSS Data Entry version 4.0, all the data 
were transferred to a database [113]. 
 
For the follow-up interviews, three more medical students worked part-time in 
the study. They were trained through reading the written guidelines and 
questionnaires, and observed one interview conducted by the project physician. 
Additionally, their first interview was supervised by the project physician. 
Regular observations of the interviewers were conducted during the 12 months 
of follow-up, including feedback on interview performance. All questionnaires 
were controlled in the same manner as the baseline interview, and data were 
entered into the database likewise after checking for errors [113]. 
 
3.5 Outcome variables 
3.5.1 Paper I - Unemployment in chronic airflow obstruction in the BOLD 
study 
The main outcome in this paper was employment status. Participants were 
asked if they had worked for income at any time the year prior to the study, or 
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if they were fulltime homemakers/care givers. All participants ≥ 65 years of 
age were defined as retirees. All others that had not worked for income or were 
not homemakers or care givers, were defined as unemployed. Retirees and 
caregivers/homemakers were excluded from the analysis, leaving a 
dichotomous outcome variable (unemployed yes/no). The variable spirometric 
CAO was analysed as the main predictor of employment status, and both 
unadjusted and adjusted comparisons between individuals with and without 
spirometric CAO were made. See section on statistical analyses, 3.7, for more 
details. 
 
3.5.2 Paper II - Productivity losses in chronic obstructive pulmonary disease 
In this paper, the main outcome was productivity loss. Number of days in 
disability pension was added from the baseline interview and the four follow-
up interviews to give total days in disability pension. For participants who were 
in paid employment, sick leave, irrespective of cause, was added for the four 
follow-up interviews to give total sick leave days. For those reporting a graded 
sick leave or disability pension, the percentage was multiplied by number of 
days absent from work. Days in sick leave and disability pension were summed 
up to give the main outcome productivity loss. 
 
3.5.3 Paper III - Incidence of COPD exacerbations 
The aim of this paper was to estimate the incidence and potential predictors of 
AECOPD. We used two definitions of an AECOPD to analyse the main 
outcome of exacerbation rates. The symptom-based definition was the same as 
in paper II (see section 3.2.3). The utilization-based exacerbations were defined 
by the use of antibiotics or corticosteroids due to respiratory disease, or by 
hospitalization due to respiratory disease. All exacerbations recorded in the 
four follow-up interviews were summed to give the number of annual 




3.5.4 Paper IV - Incremental costs of COPD and COPD exacerbations 
The main outcome in the last paper of this PhD project, was the excessive costs 
for COPD patients and COPD cases compared to control subjects. We both 
investigated the treatment-related costs, the productivity losses, and the total 
costs (treatment-related costs plus productivity losses). The treatment-related 
costs were direct costs, and included both the societal cost related to e.g. 
hospital admission, rehabilitation, or refunds of treatment, as well as the 
individual cost from for instance drug expenses, transportation and the like. 
The productivity losses, or the indirect costs, were the costs to society due to 
absenteeism from work. The treatment-related costs were calculated by 
multiplying the rates of utilization with the corresponding unit costs, see 
section 3.6 Unit costs. The productivity losses were calculated using a human-
capital approach where average wages per day based on sex, age, and 
education were multiplied by the total days of lost productivity in a year [103]. 
The mean income per day according to sex, age, and education was given for 
the year 2006 by Statistics Norway (SSB). We added 20% to the average 
income to cover for the total employers` compensation per worker [127]. All 
costs were transformed from 2006-NOK to Euros using the mean exchange rate 
for that year (8.05 NOK = 1 €). 
 
3.6 Unit costs 
For paper IV, Incremental costs of COPD exacerbations in GOLD stage 2+ 
COPD in ever-smokers of a general population, both the treatment-related 
entities and the days of lost productivity required denomination in a monetary 
unit. 
 
3.6.1 Unit costs of treatment-related items 
The annual unadjusted costs covering treatment-related items, were calculated 
by multiplying the rate of utilization per year of each item with the 
corresponding unit cost. The items we included were intended to cover total 
treatment costs, i.e. both costs payed for by the individual and by national 
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health insurance, attached under section Supplementary material. For extensive 
details, see the project physicians` dissertation [113]. 
 
For hospitalisation costs, we used the Samdata report from SINTEF (The 
Foundation for Scientific and Industrial Research at the Norwegian Institute of 
Technology) [128]. The report from SINTEF used information both from 
public and private hospitals of the Diagnosis Related Group-activity (DRG) to 
estimate the average costs per day of admission to Norwegian hospitals, 
excluding capital costs (i.e. fixed, one-time expenses due to purchase of for 
instance land, buildings, or equipment). 
 
The costs related to visits to health care providers were collected from The 
Norwegian Labour and Welfare Organisation and The Norwegian Directorate 
of Labour and Welfare [129]. All claims for the national health insurance are 
administered by them, and they provided us with estimates based on all claims 
from 2005-2006. Costs for GP-, ER-, and specialist-visits irrespective of cause 
were gathered, and the price for home visits was differentiated from office 
visits. The costs of visits to outpatient clinics were acquired from The 
Norwegian Directorate for Health and Social Affairs [130]. The estimates were 
based on data from 14 hospitals in 2007, not including capital costs. 
National estimates for the costs of home nursing services were not available, 
but The Municipality of Bergen City, Western Norway, brought forth the costs 
per hour of home nursing services as of January 1st 2008 [131]. Included in 
these costs were hourly costs, fixed costs per visit, and monthly costs. Maid 
services provided by local health authorities were paid for by the patients 
themselves, and we used self-reported expenditures for this item. 
 
To calculate drug costs, all regular medication and reliever medication was 
counted in terms of how many follow-up days they had been used. The dose 
was then set to one defined daily dose (DDD) according to the ATC/DDD-
system [132]. Additionally, intermittent medication use, and over-the-counter 
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(OTC) medication were counted and transferred to DDD. The cost per DDD 
was supplied by the Norwegian Pharmacy Association [133], and was used to 
calculate unit costs for prescription medication. For OTC medication, sales 
numbers from the pharmaceutical industry was used to calculate unit costs, 
based on information from Farmastat AS [134].  
 
Some individuals participated at the pulmonary rehabilitation programme at the 
Department of Thoracic Medicine, HUH. The programme lasted for 16 days, 
and involved both group training and education given by physicians, 
physiotherapists, nurses, and pharmacologists. Costs for individual 
participation were provided by the Pulmonary Rehabilitation unit at the 
Department of Thoracic Medicine, HUH, for year 2007 [135]. DRG-based 
costs per day were € 140 (NOK 1,120). In addition, the participants had a 
physician consultation that was billed (adding co-payment and hospital claims 
to the national health insurance) at € 155 (NOK 1,239). To calculate the prices 
in 2005- and 2006-valuta, we used the consumer price index [136]. 
Physiotherapy, either individual or in groups, was priced according to official 
costs set by the Ministry of Health and Care Services for year 2005-2006 [137]. 
 
For the few participants in the EconCOPD study that used long term oxygen 
treatment at home, the costs per year were supplied by the Department of 
Thoracic Medicine, HUH. These costs included the expenses of the equipment, 
and the personnel costs [135]. 
 
3.6.2 Unit costs of productivity losses 
Absence from work was quantified in days in paper II. In paper IV, the days of 
absenteeism, or lost productivity, were transformed to a monetary unit to give 
the costs associated with sick leave and disability pension. We used the human 
capital approach, and each day of lost productivity was valued according to the 
mean income per day by sex, age, and education provided by Statistics 
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Norway, see Appendix. An additional 20% was added to cover for employer`s 
costs [103]. 
 
3.7 Statistical analyses 
3.7.1 Unadjusted analyses 
Initial unadjusted analyses in all papers were executed to compare the 
characteristics between the groups of participants. Categorical variables were 
analysed with chi squared tests. For continuous variables, we first made 
histograms to evaluate their distribution. When the assumption of a normal 
distribution was met, we used parametric tests such as the t-test, and Analysis 
of variance (ANOVA). For continuous variables with a skewed distribution, we 
used non-parametric tests such as chi squared, Kruskal-Wallis, and Spearman´s 
correlation test. Some additional tests for trend were made in the Econ COPD 
study to assess the utilisation across the three participant groups, and for this 
purpose we used the Stata nptrend command which is a modified Wilcoxon 
rank-sum test. In the paper on unemployment across the world in the BOLD 
study, additional unadjusted, but stratified analyses were performed to assess 
the proportions who reported having a current paid job. Participants were 
stratified into high- or low-to-middle income sites and according to sex to 
visualise possible differences in job status between the sites and genders. The 
cut-off point between high- and low-to-middle income sites was set at USD 
10000 in Gross National Income Per Capita (GNIPC) of the country [138]. 
Risk ratios were estimated as the unemployment prevalence in persons with 
CAO divided by the unemployment prevalence in persons without CAO. 
 
3.7.2 Adjusted analyses 
3.7.2.1 Choice of adjustment variables 
In the analyses for paper I from the BOLD study, we investigated the 
association of the main exposure, spirometric CAO, on the outcome 
unemployment. There are several factors known to affect the unemployment 
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risk, such as higher age, female sex, cigarette smoking, and lower education 
[139, 140]. To be defined as a confounder, and hence, to be included in our 
analyses as adjustment variables, these factors also need to be associated with 
the exposure, spirometric CAO, and precede both exposure and outcome in 
time. CAO increases both with age, female sex, smoking, and lower education 
[5, 141, 142], and these are all potential confounders for our association of 
interest. The comorbidities we asked for, were heart disease, hypertension, 
diabetes mellitus, stroke, and lung cancer. It has been seen that most of these 
diseases increase the risk of unemployment [143-146], and they are known 
comorbidities in COPD [3]. Even if we cannot always be certain that these 
comorbidities precede spirometric CAO (sometimes the CAO may precede the 
comorbidities), we included also these as confounding factors in our analyses. 
Apart from these possible confounders, we furthermore included FVC in our 
analyses as a particular variable of interest. It has previously been seen that 
FVC is low in poor countries, though the aetiology behind this is not fully 
understood [147]. The proof of FVC being racially determined is weak [148], 
and it has been postulated that environmental factors may be the cause behind 
the link between poverty and low FVC (factors affecting in utero, or in early 
childhood to adolescence). As we had many participating sites from LMIC, we 
wanted to elucidate on how much of the possible association between CAO and 
unemployment that could be explained by the FVC. Finally, in our last model, 
we included respiratory symptoms to evaluate their possible association to and 
effect on the unemployment. 
 
In the three papers from the EconCOPD dataset, we included many of the same 
possible confounders as in the BOLD paper. Age, gender, smoking status, 
educational level, and comorbidities were all included based on a priori 
knowledge of the association both to the exposures and the outcomes. In paper 
II, where productivity loss was the outcome, and COPD (vs no COPD) was the 
main exposure of interest, we included exacerbations of respiratory symptoms 
as a possible predictor of productivity loss. It seems that exacerbations increase 
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the time spent off work [149], and we included it as a variable in our model to 
be able to separate the effect of this aspect from our disease of interest. In 
paper III, we included only those variables that proved significant from 
bivariate analyses with a p-value < 0.10 in the final multivariate regression 
model. This choice was made to maximize the precision of the adjustment 
estimates [150], which might be of particular importance in datasets with 
limited power. Further on, in paper III, we included maintenance therapy as a 
predictor of the outcome AECOPD. It has been seen that maintenance therapy 
reduces the risk of exacerbations[151]. Finally, in paper IV, we also included 
sample origin and vaccination status as variables of interest in the multivariate 
model of the association between COPD and costs. Both in paper II, and IV, 
we wished to investigate what would happen to the magnitude of association 
with differing levels of adjustment [150], and presented the results from several 
models with increasing subsets of adjustment variables. 
 
3.7.2.2 Paper I - Unemployment in chronic airflow obstruction in the BOLD 
study 
The main outcome in this paper was a dichotomous employment status. Using 
log-binomial generalised linear models specified as glm with fam(bin) and 
link(log), we fitted 5 models with increasing adjustment. All models adjusted 
for site as a cluster-level variable. Model 1 compared the odds ratio (OR) for 
being unemployed in subjects with CAO versus subjects without CAO, with no 
other explanatory variables included. Demographic variables; age, sex, 
education, and smoking habits were added in Model 2. Model 3 added 
comorbidities to the variables included in Model 2. In Model 4, FVC was 
added as an adjustment variable. And in the most adjusted model, Model 5, 
respiratory symptoms were added. 
 
Further on, models 2-5 were repeated for high-income and low-to-middle-
income sites separately. To evaluate site-specific and overall odds ratios for 
CAO on unemployment, we performed individual participant data meta-
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analyses with Forest plots corresponding to the models 1-5 (except the site 
adjustment). The total variation across sites due to true site-by-site 
heterogeneity (rather than what could be expected by chance alone) was 
explained by the I2 statistic. 
 
3.7.2.3 Paper II - Productivity losses in chronic obstructive pulmonary disease 
For the data on productivity losses, there were many participants with either 
zero or 365 days of lost productivity in the year of follow-up. Due to this 
skewed distribution of the outcome, we used a median quantile regression 
model to assess the incremental productivity losses in cases and patients with 
COPD versus controls. We had two main models in which the first one 
included population-based COPD cases and controls, and the second included 
hospital-recruited COPD patients and population-based controls. In all models, 
we adjusted for sex, age, education, and smoking habits. Supplemental models 
adjusted for FEV1 % predicted, number of comorbidities, and exacerbations of 
respiratory symptoms. The incremental productivity loss associated with 
having COPD was obtained by including a categorical variable indicating the 
case/control status of the participant. I.e., the change in the regression 
coefficient for this variable, equals the incremental productivity loss when 
adding COPD to the baseline productivity loss of the control subjects. 
 
3.7.2.4 Paper III - Incidence of utilization- and symptom-defined exacerbations 
As the outcome in the second paper, the distribution of the exacerbation rate in 
our third paper, was likewise skewed, with a majority of participants with 0 
exacerbations. Hence, we chose a negative binomial regression model for the 
multivariate analyses. Initially, we performed bivariate analyses of each 
potential predictor using a Kruskal-Wallis test with ties. The predictors that 
were statistically significant with a p-value of < 0.10 were included in the final 
multivariate regression model. 
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We pooled the hospital-recruited COPD patients with the population-based 
COPD cases, and adjusted for participant group to estimate the effect of sample 
population on the exacerbation rate (with the general population as the 
reference group). Models for both symptom- and utilisation-defined 
exacerbations were estimated. Adjustment variables apart from participant 
sample group included sex, age, educational level, smoking habits, pack-years, 
FEV1 % predicted, number of comorbidities, maintenance therapy, influenza 
vaccination, pneumococcal vaccination, oxygen therapy, and BMI. The results 
were given in incidence rate ratio (IRR) for each predictor, showing their 
associated relative risk of exacerbation adjusted for the other variables. 
 
3.7.2.5 Paper IV - Incremental costs of COPD exacerbations 
Also, the cost components had a skewed distribution, and we used quantile 
median regression to estimate costs attributed to exacerbations and other 
variables. With quantile median regression, the regression coefficients 
provided are in the same unit of measurement as the outcome, i.e. in monetary 
units in this case. We fitted two separate regression models, the first one 
comparing population-based COPD cases to controls, and the second 
comparing hospital-recruited COPD patients to controls. For both of these 
comparisons we calculated the treatment-related costs and the productivity 
loss-related costs separately. We made two regression models in which the 
“basic” model included adjustment for COPD severity according to GOLD-
stages II-IV, sex, age, comorbidity score, educational level, and pack-years 
smoked. The second model called “the exacerbations model”, adjusted for the 
same predictors as in the basic model, and additionally for both moderate and 
severe exacerbations. In the population sample of COPD cases there were few 
participants with severe airflow limitation (GOLD-stages III and IV). We 





3.7.3 Sample size and power calculations 
The rationale for the chosen sample size and power calculations for the 
EconCOPD study have been published previously [113]. 
Briefly, in research, a null hypothesis should be put forward before undertaking 
the analyses needed to verify or reject this null hypothesis. The sample 
collected to evaluate if the null hypothesis is true or false, needs to be of a 
certain size to be able to detect any potential effect that is truly present. There 
are mainly two errors one can commit when evaluating the null hypothesis –
rejecting the null hypothesis in favour of a false alternative hypothesis, also 
called a Type I error. The opposite is failing to reject the null hypothesis in 
favour of a true alternative hypothesis, also called a Type II error. The 
probability of committing a Type I error is known as α, and the probability of 
committing a Type II error is known as β [152]. The power of a sample is the 
probability of not making a Type II error, or with other words, the probability 
that a statistical test will pick up an effect that is truly present. Mathematically, 
power = 1 – β, and usually β is set to be 0.2. The principal factors affecting 
power are the significance level (α), the sample size, and the variance in the 
measured outcome variable. The probability of committing a type I error, α, is 
the significance level one decides to be considered as statistically significant, 
normally 0.05. With the desire of a low probability of making both a Type I 
and a Type II error, power should be as close to 1 as possible, and the 
significance level as close to 0 as possible [152]. In the EconCOPD study, 
calculations from the pilot study showed that a sample size of 85 individuals in 
each group was necessary to be able to detect a difference in costs of 150NOK 
[113] (with the aim of a β-value of 20%, and a significance level of 5%). 
 
3.7.4 Statistical software 
For all our papers, we used Stata SE for Macintosh OSX (Stata Corp, College 
Station, Texas, USA). In paper I, the version 14 was utilised, in paper II 
version 11, in paper III version 13.1, and in paper IV version 15.1.  
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4 Results 
4.1 Paper I - Unemployment in chronic airflow obstruction in the BOLD 
study 
With the aim of recruiting subjects who were representative of each local 
population in 26 sites, interview data for 22,118 participants was gathered, and 
complete data including an acceptable post-bronchodilator spirometry for 
18,710 participants was obtained.  
Of these 18,710 participants, 2123 (11.3%) had CAO. All unadjusted 
comparisons between subjects with CAO and subjects without CAO were 
significant except for the comorbidity of self-reported diabetes. Subjects with 
CAO were more often men, older, had smoked more, had a lower education, 
lower lung function, more comorbidities, higher grade of dyspnoea, more 
attacks of wheezing, and more chronic bronchitis compared to the subjects 
without CAO. 
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For the analyses on employment status, all participants aged ≥ 65 years were 
excluded, leaving 11,675 participants for remaining analyses. In total, 36.7% 
(95% CI 34.7 – 38.8) of the subjects with CAO reported having a paid job the 
past 12 months. The corresponding number for the subjects without CAO was 
53.2% (52.4 – 53.9). The unemployment rates varied substantially between the 
sites, but there was a quite consistent pattern of higher unemployment amongst 
subjects with CAO than amongst subjects without CAO, especially in high-
income sites. In LMIC, CAO was not significantly associated with 
unemployment in all sites. For instance, the unemployment rates (crude OR 
(95% CI)) in Guangzhou, China, and in Manila, Philippines, were 35.7% 
versus 49.9% (0.7 (0.4 – 1.5)), and 10.3% versus 19.5% (0.5 (0.2 – 1.4)) for the 
CAO subjects versus the non-CAO subjects, respectively. On the other hand, in 
Annaba, Algeria, and in Cape Town, South Africa, the unemployment rates 
were 50.0% versus 24.6% (2.0 (1.2 – 3.3)), and 52.2% versus 33.5% (1.6 (1.2 – 
2.0) for the CAO subjects versus the non-CAO subjects, respectively. 
More men than women reported having a paid job both in high-income and in 
low-to-middle-income countries. This difference between the genders was 
more pronounced in LMIC, and seemed to be explained by a higher proportion 
of females reporting a status as unpaid homemakers/caregivers in these sites. 
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Evaluating the adjusted odds ratio of being unemployed according to CAO 
status, we used log-binomial generalised linear models with an increasing 
number of predictors. The first model, adjusting for site, gave an OR (95% CI) 
for being unemployed of 1.79 (1.41 – 2.27) for the participants with CAO. 
Further adjustment with the demographic factors sex, age, smoking habits, and 
education (model 2), reduced the OR to 1.44 (1.15 – 1.81), though it remained 
statistically significant. In model 3, we added adjustment for comorbidities, and 
in model 4 additional adjustment for FVC in % of predicted was made, but 
none of these variables significantly changed the OR of unemployment 
amongst subjects with CAO which remained at 1.43 (1.14 – 1.79) in model 4. 
Further adjustment with respiratory symptoms in model 5, did reduce the OR 
for unemployment to 1.26 (1.00 – 1.57), but the association between 
unemployment and CAO was still statistically significant. 
All the multivariate regression models were repeated with stratification 
between high- and low-to-middle-income countries. In these stratified and 
adjusted models, CAO was a significant risk factor for unemployment in all 
high-income countries. Female sex and increasing age were the most important 
risk factors of unemployment in LMIC with overall ORs 3.23 (2.66 – 3.91) and 
2.20 (1.96 – 2.47), respectively, in model 4. In high-income countries, 
increasing age and lower education were important risk factors of being 
unemployed. A 10-year increment in age was associated with an OR of being 
unemployed of 4.02 (3.53 – 4.57), and the OR of unemployment for primary 
school education compared to university education, was 3.86 (2.80 – 5.30), 
with adjustments as in model 4. 
Examining the heterogeneity between the sites, we performed individual 
participant data meta-analyses with Forest plots of odds ratios and overall I2 
statistics. As an equivalent to the model 4 mentioned above, though without 
site-adjustment, the overall adjusted OR for unemployment amongst CAO 
subjects was 1.41 (1.18 – 1.69), with an I2 statistic of 12.9% (as a 
quantification of the site-by-site heterogeneity). 
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4.2 Paper II - Productivity losses in chronic obstructive pulmonary disease 
For the analysis of productivity losses in the prospective observational study 
EconCOPD, we focused on the data of the 102 hospital-recruited COPD 
patients, 53 population-based COPD cases, and 107 control subjects who were 
below the Norwegian retirement age of 67 years. 
Unadjusted comparisons between the groups showed that there were no sex 
differences between them. The hospital-recruited COPD patients were 
significantly older, had a lower educational level, lower lung function, more 
comorbid conditions, and experienced more events of exacerbations of 
respiratory symptoms, both when using ANOVA, chi squared, or Kruskal-
Wallis as appropriate. Also tests for trend using nptrend confirmed significant 
differences between the sample groups (hospital patients > population-based 
patients > controls).  
At baseline, the proportions reporting having a paid job amongst the hospital-
recruited COPD patients, the population-based COPD cases, and the controls 
were 31%, 55%, and 87%, respectively. On the other hand, the proportions 
reporting receiving a disability pension at baseline were 65%, 30%, and 7%, 
among the respective groups.  
During one year of follow-up, the mean days (SD) in sick leave were 12.6 (30), 
19.3 (55.4), and 15.7 (36.4), for the patients, the cases, and the controls, 
respectively. The mean number of days (SD) with a disability pension during 
the year of follow-up was 228.6 (170.3), 100.8 (156.3), and 23.4 (83.1), 
respectively. The median number of days (IQR) with a disability pension 
during follow-up, was 365 (365), 0 (256), and 0 (0), respectively. 
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The days in sick leave and days with a disability pension were summed in our 
main outcome -days of productivity loss. This outcome was quite 
asymmetrically distributed, with 56% of hospital-recruited COPD patients 
having 365 days of lost productivity, and only 8% of this subsample having 0 
days of lost productivity. Meanwhile, 38% of the population-based COPD 
cases had 0 days of lost productivity. Anyhow, there was a consistent and 
significant trend that the hospital-recruited COPD patients had the highest and 
the controls had the lowest number of days lost (test for trend, p<0.001). 
In our adjusted analyses, median quantile regression gave the incremental 
productivity losses associated with having COPD. Adjustment variables were 
sex, age, educational level, and smoking habits. Comparing population-based 
COPD cases to controls, the presence of post-bronchodilator COPD was 
associated with an increase in productivity losses of 5.8 days (95% CI 1.4 – 
10.1). Comparing hospital-recruited COPD patients to controls, having COPD 
was associated with an increase in productivity losses of 330.6 days (327.8 – 
333.3). In both comparisons, female sex and lower education were also 
associated with a significantly increased productivity loss after adjustment for 
the other variables. 
Examining the effect of comorbid conditions and events of exacerbations of 
respiratory symptoms on the association between COPD and productivity 
losses in the initial analyses, we found that amongst the population-based 
COPD cases the association was no longer statistically significant. Amongst 
the hospital-recruited COPD patients, the association was reduced to 312 days 
from the original 330 days, a reduction of 5.5%. Per added comorbid condition, 
the incremental days of lost productivity were increased by 5.0 (2.6 – 7.4), and 
5.1 (3.2 – 7.1) amongst the population-based COPD cases and the hospital-
recruited COPD patients, respectively. 
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4.3 Paper III – Incidence of utilization- and symptom-defined COPD 
exacerbations 
In this prospective observational study with one year of follow-up, including 
participants from three sample groups, we gathered questionnaire information 
and spirometry data for a total of 205 COPD patients from a hospital register, 
81 COPD cases from a general population, and 132 control subjects from the 
same general population. 
Unadjusted comparisons between the groups showed that there were no sex 
differences between them. The hospital-recruited COPD patients were 
significantly older, had smoked more packyears but were more frequently 
former smokers, had a lower educational level, lower lung function, more 
comorbid conditions, experienced both more resource-defined and more 
symptom-defined exacerbations, used more maintenance therapy, had more 
frequently undergone vaccination, and were more often underweight, when 
compared to population-based COPD cases and to controls. 
Incidence rates of exacerbations per person per year for the population-based 
COPD cases and for the hospital-recruited COPD patients, were 0.4 and 1.0 for 
the utilization-defined exacerbations, and 2.9 and 5.9 for the symptom-defined 
exacerbations, respectively (all p-values for the comparisons between the 
sample groups were < 0.001). The control subjects also met the criteria for 
having an exacerbation at a rate of 0.1 per person per year, and 0.7 per person 
per year for the two respective definitions of an exacerbation. 
A majority of participants experienced zero exacerbations during the follow-up 
period. Using the utilization-based definition 349 participants (83%) had zero 
exacerbations, and with the symptom-based definition 264 participants (63%) 
had zero exacerbations.  
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Due to the skewness of the data, we applied a negative binomial regression 
model for the multivariate analyses. COPD patients from the hospital register 
and COPD cases from the population sample were pooled together, and 
adjustment was made for recruitment source in addition to the other adjustment 
variables (sex, age, smoking status, GOLD-stage, comorbidities, maintenance 
therapy, influenza vaccination, and pneumococcal vaccination). Packyears, 
educational level, and BMI were omitted from the multivariate regression 
models due to insignificant results in the prior bivariate analysis.  
The results were given in incidence rate ratios (IRRs) for experiencing an acute 
exacerbation of COPD (AECOPD) for each variable compared to its reference. 
With the resource-based exacerbation definition, the IRR (95% CI) was 1.59 
(1.00 – 2.52) for experiencing an AECOPD amongst the hospital-recruited 
COPD patients compared to the population-based COPD, whilst using the 
symptom-based definition gave an IRR of 1.78 (1.20 – 2.64) for the same 
comparison.  
For both exacerbation definitions, the variables GOLD-stage, and receiving 
maintenance therapy were significantly associated with an increased IRR of 
AECOPD. With the resource-based definition, GOLD-stage II was associated 
with an IRR of 2.45 (1.22 – 4.95), GOLD-stage III 3.43 (1.59 – 7.38), and 
GOLD-stage IV 5.67 (2.58 – 12.48). The same pattern of increasing risk of 
experiencing an exacerbation with increasing airflow limitation was seen with 
the symptom-based definition, with IRRs of 3.08 (1.96 – 4.84), 3.45 (1.92 – 
6.18), and 4.00 (2.09 – 7.66) for GOLD-stages II, III, and IV, respectively. 
With the resource-based definition, female sex was significantly associated 
with an elevated risk of having an AECOPD, IRR 1.57 (1.15 – 2.14). This was 
not the case when employing the symptom-based definition, but instead, 
increasing age and having taken the influenza vaccine were negatively 
associated with the risk of AECOPD with IRRs of 0.71 (0.60 – 0.83), and 0.71 
(0.50 – 1.00), respectively. 
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4.4 Paper IV - Incremental costs of COPD exacerbations 
In the final paper, we sought to estimate the costs of COPD exacerbations in 
the 205 COPD patients from a hospital register, and 81 COPD cases in the 
EconCOPD study. The comparison to the 132 controls provided the 
opportunity to estimate incremental costs. 
The annual unadjusted costs per person were significantly higher among the 
hospital-recruited COPD patients compared to the population-based COPD 
cases, and to the control subjects. For instance, mean hospitalisation costs per 
person per year were 5278 € for a hospital-recruited COPD patient, while it 
was 1812 € for a population-based COPD case. The total mean annual 
treatment-related costs summed up to 9504 € per hospital-recruited COPD 
patient, 3829 € per population-based COPD case, and 2246 € per control 
subject. The annual long-term disease-related productivity losses amounted to 
13,411 € per hospital-recruited COPD patient, 7777 € per population-based 
COPD case, and 2094 € per control subject. The total mean annual costs of 
productivity losses were 17,014 € per hospital-recruited COPD patient, 11,192 
€ per population-based COPD case, and 4494 € per control subject. The total 
mean costs per person, i.e. the sum of the treatment-related costs and the 
productivity losses, were 26,518 € for the hospital patients, 15,021 € for the 
population cases, and 6740 € for the controls, respectively (p<0.001). 
In the multivariable analyses, we used median regression to model the 
incremental costs of COPD. We made 4 main models, each of which had two 
versions, one with basic adjustments (FEV1, sex, age, comorbidities, education, 
and packyears), called the basic model, and the second version with additional 
adjustment for moderate and severe exacerbations, called the exacerbation 
model.  
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In the first main model, we estimated the adjusted incremental treatment-
related costs comparing population-based cases to controls. The basic model 
gave an incremental cost of 490 € (95% CI 132 – 849 €) associated with 
GOLD-stage II, and 1938 € (1266 – 2610) associated with GOLD stages III/IV. 
Adjusting for moderate and severe exacerbations, these numbers fell to 462 € 
and 1684 €, respectively. In other words, exacerbations explained 6% of the 
treatment-related costs in GOLD-stage II, and 13% of the treatment-related 
costs in GOLD-stages III and IV. Female sex and comorbidities were also 
significant cost drivers in the first model. 
The next main model, estimated the incremental productivity losses comparing 
population-based COPD cases to controls. In the basic model, no significant 
incremental productivity costs were associated with GOLD-stage II. But for 
participants in GOLD-stage III and IV, the incremental costs of the annual 
productivity losses were 46,215 € (30,190 – 62,240). When adjusting for 
moderate exacerbations, this cost lost its` significance, demonstrating that 
moderate exacerbations explained all productivity-related costs for the COPD 
cases. 
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In the third main model, the treatment-related costs for hospital-recruited 
COPD patients were compared to that of the controls. In these analyses, we did 
not need to pool GOLD-stage III and IV participants together, as we did for the 
population cases. In the basic model, there was a significant incremental cost 
associated with GOLD-stages II, III, and IV at 2252 € (947 – 3557), 3221 € 
(1773 – 4669), and 5684 € (3955 – 7412), respectively. Adjusting for 
exacerbations, these costs were reduced to 1646 € (428 – 2863), 1943 € (557 – 
3329), and 3539 € (1771 – 5308), respectively. In other words, the treatment-
related costs associated with the GOLD-stages remained statistically 
significant, but were reduced with 27%, 40%, and 48% when adjusting for 
exacerbations, for the respective grades of airflow limitation. Comorbidities 
were an additional significant cost driver in this comparison, both in the basic 
and in the exacerbations model. The corresponding incremental costs were 694 
€ (254 – 1134) per comorbid condition added in the basic model, and 714 € 
(317 – 1111) per comorbid condition added in the exacerbations model. 
The fourth and last main model, estimated the incremental costs of productivity 
losses for the hospital patients compared to the controls. Again, increasing 
airflow limitation resulted in increasing costs. For GOLD-stage II, III, and IV, 
the incremental costs of productivity losses were 28,845 € (19,383 – 38,307), 
29,570 € (18,759 – 40,382), and 48,338 € (36,548 – 60,128), respectively. 









In this section, the methodological issues will be discussed firstly. This will 
include study design, possible errors that can be made in epidemiology, and 
statistical and health economic considerations. Secondly, the main results will 
be discussed. This includes a discussion of the association between COPD and 
disease burden in the form of unemployment and productivity losses, the 
measures of incidence of AECOPD, and the cost estimates and cost drivers. 
Finally, the effect of sample size will be discussed. 
5.1 Methodological considerations 
5.1.1 Study design 
In this thesis, we have utilised two datasets that both included participants from 
a general population. The BOLD study was a cross-sectional study including 
non-institutionalised persons from multiple study centres around the world. 
Cross-sectional studies are like snap shots of reality reflecting a situation in 
that specific moment. As such, cross-sectional studies cannot prove if the 
connection between an assumed predictor and an outcome is causative, or 
which of them arose first in time. Our research objective in paper I, was to 
describe the rates of unemployment in subjects without CAO and in subjects 
with CAO, and to analyse if there was an association between the assumed 
predictor CAO and the outcome of unemployment. As a descriptive study of 
associations, the cross-sectional design is adequate and serves to answer the 
aims of the study.  
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The rate of unemployment we found was significantly different between the 
healthy subjects and the CAO subjects, but we cannot prove that having CAO 
predicts a higher risk of unemployment. There is a possibility of 
unemployment arising beforehand and being the cause of CAO. There is some 
evidence that economic hardship leads to health-endangering personal 
behaviour, like increased smoking [153]. Yet, lacking the proof of temporality, 
we would like to argue that a condition like CAO, that takes decades to develop 
and that inflicts daily symptoms of heavy burden, is more likely to be the cause 
of unemployment, and not vice versa. 
The second dataset we utilised, was the EconCOPD study. This was an 
observational, prospective cohort study that followed the participants for one 
year, i.e. with a longitudinal design. The participants were recruited from two 
distinct sources, COPD patients from a hospital register, and both COPD cases 
and control subjects from a general population, and comparisons between these 
samples were made. Cohort studies are in general more time-consuming and 
expensive than case-control studies and may be presented as of inferior quality 
compared to randomized controlled trials. But when there is no intervention to 
be evaluated, cohort studies are considered to give the most reliable outcomes 
in observational epidemiology. During the follow-up time, cross-sections can 
be made at certain time intervals in which information of interest is collected 
and used to calculate the longitudinal occurrence of the disease in question.  
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The aims we sought to illuminate using the EconCOPD study, were firstly to 
estimate the incremental productivity losses of COPD and its predictors. 
Secondly, we aimed to estimate the impact of recruitment source and outcome 
definition on the incidence of acute exacerbations of COPD and possible 
predictors of AECOPD. Thirdly, we wanted to estimate the treatment- and 
productivity-related costs associated with COPD in two different samples, and 
to evaluate the association between the costs and moderate and severe 
exacerbations. A cohort study with two sampling sources enabled us to reach 
these aims in an adequate manner. All COPD cases and a random sample of 
control subjects from the HCRHS follow-up in 2003-2005 were invited. 
Additionally, a random sample of COPD patients from the hospital registry 
was also invited. The participant characteristics that differed between the 
groups were adjusted for in multiple regression models reducing the risk of 
confounding. To reduce the risk of recall bias, interviews were made at an 
interval of three months. An alternative approach would have been a matched 
case-control study. With a matched case-control design, 2-4 controls are 
normally recommended per case, and would have made such a design more 
expensive, and would have required a larger number of controls than in the 
longitudinal cohort design we chose. Another alternative would have been to 
investigate these issues in a retrospective manner, e.g. by collecting data from 
registries. Retrospective studies have the advantage of being cheaper, and less 
time-consuming than prospective studies. Prospective studies, on the other 
hand, have fewer possible sources of bias and confounding, less missing data, 






5.1.2 Errors in epidemiology 
Errors can occur when performing research in epidemiology, by chance, so 
called random errors, or systematically. Errors may disturb the results of the 
research, and researchers might as a consequence see associations that are non-
causal. 
 
5.1.2.1 Random error and precision 
Precision in epidemiology refers to how close repeated measurements of the 
same object are to each other [155], and is also known as reliability. Human 
beings and equipment can give rise to imprecise measurements, and it is crucial 
to minimize these errors. With low precision, there is a greater spread of the 
results of each measurement. But the mean value of measurements will 
inevitably deviate less from the true value when the number of measurements 
increases. 
Random errors are those that occur by chance. As such, they do not recur, and 
if truly random, they are distributed in both directions compared to the truth 
(the reason why they are also called non-differential errors/misclassification) 
[155, 156]. With large samples of high power, random errors should not cause 
erroneous associations. Though, with small samples, or outcomes that are rare, 
random errors may be a source of concern. 
Most variables are subject to random error which may arise at different stages 
of the data collection. Demographic information such as sex, age, and 
educational level should not be substantially prone to random errors. Other 
variables, such as packyears smoked, exact number of days in sick leave, lung 
function measurements, or BMI, might be affected by random errors. Still, with 
the sample size we had both in the BOLD study and in the EconCOPD study, it 
is hard to believe that the results should be affected in only one or the other 
direction by these unpredictable errors. 
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5.1.2.2 Systematic error and validity 
The validity of epidemiologic research can be divided in two. External validity 
deals with how representative the results of a study are for the reference 
population. In other words, how generalizable the results are. In the planning 
and design of studies, choices should be made to enhance the future external 
validity of the findings. Internal validity, however, concerns how representative 
the results are for the participants of the study.  
The high internal validity of randomized controlled trials is ensured by the 
random allocation of participants into study arms (e.g. active treatment vs 
placebo). Thus, even unmeasured variables are in principle evenly distributed 
over these arms, and with participants behaving obediently there will be no 
trouble with the internal validity.  
In epidemiological, real world data, however, there will always be some 
amount of systematic error due to comparison between non-random groups. 
The validity in such studies is based on knowing how these groups differ, but 
these differences are prone to both random and systematic measurement error, 
of which the latter may disturb the internal validity. These systematic errors are 
often referred to as biases. 
If the systematic errors are sufficiently substantial, type-I or type-II errors can 
occur. A type-I error is defined as falsely rejecting a true null hypothesis of no 
association, and a type-II error as accepting a false null hypothesis. 
5.1.2.3 External validity 
In the BOLD study, the reference, or target, population was adults over 40 
years in a wide range of low, middle, and high income countries across the 
world. Each site used an approved method to recruit participants that were not 
institutionalised and 40 years or older. Additionally, the participants should 
have an equal distribution of demographic variables compared to the general 
population at each site to secure that the study have high external validity. 
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 In Norway, the BOLD participants were recruited from the 2003-2005 follow-
up of the HCRHS. The participants in the HCRHS study, were initially 
recruited back in 1985. In 2003-2005, the third follow-up of these participants 
was accomplished. One can put questions to how representative this study 
sample was in the early 2000s, after two decades of follow-up. Those not lost 
to follow-up, or who had not died, and chose to continue participating, might 
possess particular characteristics differentiating them from those who did not, 
or could not, keep on participating. To minimize this risk, a great effort was put 
down to maintain high response rates. Additionally, it was ensured that the 
sample had sufficient similarity in the distribution of age, sex, and smoking 
habits to that of the Norwegian population[4]. 
The EconCOPD study involved three subsamples of participants. The 
population-based control subjects and COPD cases had the ever-smoking 
population above the age of 40 years in Hordaland county as its reference 
population. Ever-smoking subjects above the age of 40, and treated for COPD 
at a university hospital, were represented by the third subsample of hospital-
based COPD patients. The EconCOPD study also recruited its participants 
from the third follow-up of the HCRHS, and the same reflections about the 
representativeness of the study participants in the BOLD study, are valid here. 
Table 3 shows the comparison of age, sex, and educational level between the 
2003-2005 HCRHS follow-up and Norwegian national survey data [113]. 
Though there were some small differences, it seems quite impartial to say that 
the 2003-2005 HCRHS follow-up was relatively representative of the 
Norwegian adult population as a whole. 
5.1.2.4 Internal validity 
Systematic errors, or bias, might cancel, reduce, or amplify the associations or 
effects studied. Hence, minimizing these errors, improves the internal validity 
of a study. Systematic errors can be divided in three main types –information 
bias, selection bias, and confounding [156]. 
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5.1.2.5 Information bias 
Information bias appears when there are systematic errors in the measurement 
of the variables in a study. The result of information bias would be that the 
associations are wrongfully displaced in one or the other direction [156]. 
Demographic variables are less prone to systematic errors compared to other 
variables that involve some kind of measurement, using either machines or 
estimated by humans.  
In this PhD project, a potentially consequential measurement error would be if 
the spirometric values were systematically incorrect. To minimize this risk, all 
spirometers were calibrated daily, or before each manoeuvre. All 
measurements were performed according to strict standards following the ATS 
criteria [157], and personnel were trained to obtain acceptable and reproducible 
results. In the BOLD study, there was additional quality control of every 
manoeuvre at a pulmonary function reading centre. In addition to the actual 
physical measurements, the values accomplished by spirometry are also made 
relative by comparing them to a reference population, generating values of 
FEV1 and FVC in “percent of predicted”. The reference population chosen 
might not be correct for all participants, and can be a source of 
misclassification of participants into the COPD-group or the healthy group. We 
think such misclassification can be of greater importance in international 
studies where ethnicity varies more for the participants than in studies like the 
EconCOPD where most participants were of Norwegian ethnicity.  
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Furthermore, interpretation of the spirometric values for diagnostic purposes 
implies methodological choices that might differ between studies (i.e. how to 
define obstruction). Choosing the fixed ratio to define obstruction, compared to 
the LLN, might affect the results in the direction of having increased false 
positive results amongst elderly people, and more young people being 
classified as false negative [18, 19]. In clinical practice, many now advocate 
the use of LLN [158], and it is recommended to be included in the new 
Norwegian guideline on COPD treatment that is currently under preparation 
[159]. The average ages in the EconCOPD, were 57, 63, and 67 years for the 
controls, COPD cases, and COPD patients. Thus, one might argue that at least 
for the controls and cases, there should not be many false positives. The COPD 
patients, though, that were recruited from the hospital register, were somewhat 
older. The fact that 50% of these patients had an FEV1 < 50% of predicted, 
make the group of participants “available” to misclassification much smaller, 
as it is very unlikely to misclassify someone who already has severe or very 
severe airflow limitation to not having any limitation at all. 
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In the EconCOPD study, the results from spirometries performed in the 2003-
05 HCRHS follow-up were used. During the short time-span between the two 
studies, spirometry results might have changed. It is known that individual 
variation can be substantial when performing spirometry as it depends much 
upon technique and execution. Hence, there might be some misclassification of 
lung function for the participants in the EconCOPD study. Most likely, such 
errors will occur randomly. Subjects with mild disease would probably have 
been more prone to these errors than the participants in the EconCOPD study, 
where all COPD cases and patients had an FEV1 < 80% of predicted. 
Comparing the general population sample to the hospital sample, we think that 
the population sample is more vulnerable to measuring errors in spirometry 
since values in a less severely sick population will come closer to the threshold 
for FEV1/FVC. If a greater proportion from the general population sample was 
misclassified as sick than in the hospital sample, these individuals would 
probably consume very little health care services and give rise to an 
underestimation of the costs associated with COPD. All in all, we believe that 
possible misclassification of participants has not been substantial enough to 
alter our results significantly. 
If some variables were prone to be either overreported or underreported, our 
results could have been pulled in one direction compared to the truth. In the 
BOLD paper, the question identifying the study population asked for “any paid 
work” the last year, not differentiating between full-time and part-time work, 
and, hence, if some participants needed to reduce their work participation due 
to CAO, they were still registered as employed in our dataset. This can have 
led to an underestimation of the association between CAO and unemployment.  
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For the paper on incidence of AECOPD, we did the analyses both with a 
symptom-based definition, and a resource-based definition. Symptoms are 
subjective, and only a proportion of patients will seek help based on them. By 
necessity, there will be fewer exacerbations with a resource-based definition of 
AECOPD compared to a symptom-based definition. One could argue that the 
difference seen is the difference made up of an information bias that lies 
incorporated in a symptom-based definition. Personal behaviour, though, might 
also be an important explanatory factor to the difference seen in exacerbation 
rate between the two definitions applied. Some are prone to seek medical 
advice earlier than others, or for differing grades of symptoms. Such 
behavioural variability has been seen between the genders [160], and between 
varying age groups [161]. 
Some kind of self-reported information was used in all four papers. Such 
information is dependent on the participant´s memory, and is, hence, exposed 
to being not perfectly correct. This is called recall bias.  
In the prospective EconCOPD study, we contacted the participants at relatively 
short intervals (every three months) to minimize the risk of recall bias. A 
comprehensive review of previous studies on patient self-reports to quantify 
health care utilisation, was performed by Evans et al [162]. Looking upon the 
length of the recollection period and the validity of the results, a three-month 
interval was considered fair for utilisation data. In addition, results from the 
EconCOPD pilot study indicated that the recall interval was sufficient [119]. 
Finally, the Hawthorne effect might have made the participants report 
differently due to the fact that they were aware of being observed [163]. Little 
is known about the magnitude of this effect, and it is difficult to eliminate in 
real life studies. Only blinded randomised controlled trials are free of its 
influence. 
 88 
Further on, it is known that the more serious an event is, the more likely it is 
remembered [162]. We found that the participants with lower lung function had 
more severe exacerbation events. This could have skewed the results toward 
more events being recalled in those with more severe COPD, eventually 
resulting in more accurate utilisation of health care services for these 
participants compared to those with a higher FEV1 and less severe events that 
could more easily be forgotten, or underreported. Opposed to this, it has also 
been seen that as the utilisation of health care increases, so does the 
underreporting, i.e. the more health care services the patients use, the higher 
the tendency to forget or underreport these events [164]. The net effect of 
better memory for more severe events and increased underreporting the more 
events one experience, is not easily detangled. 
 
5.1.2.6 Selection bias 
If selecting participants, or groups of individuals, for research is performed in 
such a way that the sample obtained is not representative of the target 
population, bias is introduced to the research [155, 156]. This type of bias is 
referred to as selection bias.  
Intending to avoid selection bias, one can use randomisation in selecting 
subgroups from the population one wishes to study. If these subgroups are 
equivalent to the population they are supposed to represent when it comes to 
major characteristics, selection bias is less probable to affect the results. When 
performing cohort studies over time, it is inevitable to lose some participants 
along the way. It is essential to investigate who is lost and who complete the 
follow-up to be able to evaluate if the results can have been affected by the loss 
of participants. If there is a differential loss of participants between the exposed 
group and the non-exposed group, the results are affected. Usually, though, the 
relationship between exposure and outcome in non-responders is not known, 
and hence, selection bias cannot be accurately calculated.  
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Another aspect of selection bias, is self-selection or volunteer bias that can 
threat the validity of research if self-selection is related to the exposure or the 
outcome that is being studied [155]. It is known that individuals volunteering to 
participate in research are more often women, younger, healthier, and with a 
higher education [165-167]. 
EconCOPD recruited its participants from the third follow-up of the HCRHS, 
and from the patient register at HUH. Originally, the HCRHS study invited a 
simple randomised sample of 1.9% of the adult population aged 15 to 70 years 
residing in Hordaland County in 1985 (n=4992). In the second follow-up, 3370 
subjects from the original sample whom resided in Bergen and immediate 
vicinity were invited. Among the survivors, 2819 (89%) responded. The third 
follow-up invited the responders from the second follow-up, and 69% of the 
invited subjects participated. Approximately 20 years had passed from the 
beginning of the HCRHS study until the initiation of the EconCOPD study, and 
it is likely that some survivor bias affected who could continue to participate in 
the study. Previous studies have found that more healthy individuals with a 
better prognosis are overrepresented in longitudinal cohorts  [168, 169]. If the 
EconCOPD study included more healthy individuals than what would be seen 
in the general population of Hordaland County, the prevalence of COPD and 
the health care utilisation in this sample would be underestimated resulting in 
weaker associations than what truly may be present in the target population, 
and possibly exaggerating the differences between hospital recruited COPD 
patients and population-based COPD cases. 
 90 
In the EconCOPD study, recruitment was made by telephone and invitation 
letters, and only a low proportion of participants was not reached. Non-
response analyses comparing age, sex, and lung function between responders 
and non-responders for the three subsamples of the EconCOPD are shown in 
Table 4 (reprinted with permission [113]). Amongst the hospital-recruited 
COPD patients, both non-response, withdrawal during follow-up, and death 
during follow-up, were associated with a significantly higher age (p<0.05). In 
addition, in those that died during follow-up, FEV1 % of predicted was lower 
than in survivors. Subjects that died during the year of follow-up were not 
included in our analyses. 
For the population-based subsamples, comparing death during follow-up to 
complete follow-up, death was significantly associated with higher age in the 
group of COPD cases. Neither non-response nor withdrawal in either 
population-based subsample was associated with age. In both of the two 
population-based subsamples, non-response, withdrawal, and death, were 
unassociated with sex, lung function, or smoking habits (Table 4). All in all, 
there was no consistent pattern of differences between non-responders and 
participants suggesting selection bias in our results, though the extent of a 
potential survivor bias is not known. 
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In the BOLD study, each site carried out a sampling design ensuring selection 
of a sample representative of the local general population. Some sites used 
simple randomisation, some stratified random sampling, others cluster 
sampling, or random digit dialling (see Appendix for details). The Norwegian 
site in Bergen, used a stratified random sample of responders and non-
responders to the third follow-up of the HCRHS, and had a response rate with 
complete spirometry and questionnaire data for 68%. A study by Eagan et al. 
on the original HCRHS cohort, found that unemployed individuals tended to 
respond later to participation in research compared to employed individuals 
[170]. If employment status affected the response rates in the BOLD study, our 
results on unemployment across the world could have been affected by 
selection bias. Inclusion of fewer unemployed participants could result in an 
underestimation of the association to CAO. Further on, we chose a cut-off for 
the retirement age at 65 years. This cut-off was broadly discussed in the author 
group, as there was no standard age of retirement across the sites. In Norway, 
the normal retirement age is 67 years, whilst some sites in the BOLD study 
reported that their participants nearly never would retire due to the lack of 
government social support, whilst others again had a lower retirement age than 
Norway. The cut-off at 65 years was chosen as a pragmatic compromise.  The 
net effect of this cut-off age on the results is not known, but if any effect on the 
results, there must be a differing relationship between CAO and unemployment 
according to these age groups. CAO and unemployment increases with age, 
and if the cut-off was set too low, we might have included fewer participants 







Table 3: Comparison of demographic variables in responders ≥ 40 years in the 2003-05 
HCRHS follow-up and in national survey data. 
 HCRHS ≥ 40 yrs Norway ≥ 40 yrs 
Age, yrs   
40-49, N (%) 453 (32) 639,053 (30) 
50-59, N (%) 447 (32) 595,423 (28) 
60-69, N (%) 267 (19) 374,975 (18) 
70-79, N (%) 180 (13) 299,162 (14) 
 66 (5) 209,186 (10) 
Mean age, yrs 57 (57-58)  
Male gender, % 725 (51) 1,014,299 (48) 
Education   
Primary, N (%) 379 (27) 712,771 (33) 
High-School, N (%) 651 (46) 976,149 (45) 
University, N (%) 382 (27) 468,429 (22) 
Smoking habits   
Current, N (%) 407 (29) (26) 
Ex-smoker, N (%) 484 (34)  
Never-smoker, N (%) 505 (36)  




Table 4: Non-response analyses in EconCOPD by participation status. 





Declined vs accepted 
invitation, N 81 vs 245 21 vs 90  13 vs 136 
Age p=0.009 NS NS 
Sex NS NS NS 
FEV1 % pred NS NS NS 
Lung function group NS NS NS 
Withdrew/deceased vs 
complete follow-up, N 40 vs 205 9 vs 81 4 vs 132 
Age p=0.0002 NS NS 
Sex NS NS NS 
Smoking habits NS NS NS 
Pack years NS NS NS 
FEV1 % pred NS NS NS 
Lung function group NS NS NS 
Deceased vs complete 
follow-up, N 13 vs 205 2 vs 81 No deceased 
Age p=0.02 p=0.02 NA 
Sex NS NS NA 
Smoking habits NS NS NA 
 Pack years NS NS NA 
 FEV1 % pred 0.009 NS NA 
 Lung function group 0.008 NS NA 
NS; non-significant (p>0.05). NA; not applicable. FEV1; forced expiratory volume in one second. 1 pack year = 20 cigarettes/day 
during 1 year. [113]. 
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5.1.2.7 Confounding 
Confounding is the phenomenon observed when a variable complies with three 
criteria: 1) It is an independent risk factor for the outcome, 2) it is associated 
with the exposure in the source population, and 3) it is not affected by the 
exposure or the outcome. Confounders may bias or blur the results. For 
example, hypertension is a known cause of cardiovascular disease, and so is 
smoking. But smoking is also a cause of hypertension, so when investigating 
the effect of hypertension on cardiovascular disease, one must have 
information on smoking too, as it is a possible confounder in this example. 
Both in the stage of design and the stage of analysis, it is important to control 
for confounding to minimize bias. Only in contrafactual thinking, which is 
impossible per se, confounding and biases can be completely removed. At the 
time of designing a study, one can choose to use randomisation, restriction or 
matching, to reduce confounding. Randomisation refers to assigning the study 
subjects randomly into groups of exposure and non-exposure, and hence 
creating groups that have comparable distribution of key characteristics. By 
restriction, participants are chosen so that confounding by known confounders 
are eliminated. E.g., if age or sex is known confounders for an association, only 
participants of one sex or of a specific age interval are chosen to participate. 
Finally, by matching, a control group that is similar in confounding variables to 
the exposed group, is included for comparison. 
At the stage of analysis, confounding can be controlled for by stratification, 
standardisation, or adjustment in multiple regression. With stratification, one 
can create two groups that differ in the occurrence of a known confounder. For 
instance, if smoking is a confounder of the association between hypertension 
and cardiovascular disease, one can analyse the results stratified by smoking, 
and look for differences. 
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In some occasions, one would like to compare results across countries, or 
across any groups of individuals. For instance, one could be interested in 
comparing the mortality rates due to road accidents in two countries. But the 
two populations are normally not immediately comparable, and this is where 
standardisation can come in handy. By using a standard population, two 
populations that are not necessarily comparable can be compared via the 
standard population. 
Last but not least, statistical methods of multiple regression analysis can 
control for confounding. Especially when there are multiple confounders to 
adjust for, stratification is less suitable. With multiple regression analysis, 
several confounders or covariates can be adjusted for at the same time to 
elucidate the effect of each one of them on the outcome of interest. Information 
about the confounding factors must have been collected during the study. 
Depending on the outcome, be it a continuous, categorical or time-to-event 
outcome, one need to choose a regression method that is suitable for every 
occasion. Attention must be paid to the risk of overadjusting and the possibility 
of introducing bias when doing multiple adjustments. Additionally, the 
statistical power is reduced when adjusting for multiple covariates, and the 
sample size must be large enough to be able to handle this [171]. 
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In the BOLD study, several techniques were used to control for confounding. 
In our multiple regression model, we adjusted for an increasing number of 
covariates in a total of five models. These possible confounders were site, 
CAO, age, sex, education, smoking habits, comorbidities, FVC, and respiratory 
symptoms. Our main predictor of interest was CAO. Further, previous research 
has seen that educational level, age, sex, and social class is related to the risk of 
unemployment, and hence were confounders that needed to be adjusted for in 
our multiple regression models. We did not have information on social class, 
however it has been argued that education is the most important precondition to 
social class, and hence that education at least partially explains the association 
between social class and unemployment [172]. Comorbidities, FVC, and 
respiratory symptoms were added to evaluate their effect on the result. Apart 
from adjustment, we performed stratified analysis for the association between 
CAO and unemployment in different parts of the world according to income 
status. There was an overall association between CAO and unemployment after 
adjusting for sex, age, education, smoking habits, comorbidities, and FVC. 
When stratifying on income status of the site, this association was less clear. 
The association was statistically significant in all high-income sites, but not in 
all LMIC. One could argue that the sites in the BOLD study are so 
fundamentally different when it comes to traditions and culture, economy, 
welfare schemes, and sociodemographic factors, that a comparison is futile. 
Evaluating the results from each site, we were made aware of some basic 
differences between the sites, and thus, we performed analyses both with a 
stratification on income, and on sex, to further describe the situation in the 
various sites. Using the strata high- and low-to-middle income, the 
confounding effect of income on unemployment was reduced, though we only 
had information on income as an ecological variable (per capita per country), 
not per participant. Additional site-heterogeneity was elucidated using 
individual participant data meta-analysis displaying OR for CAO on 
unemployment in Forest plots. And finally, to evaluate if age could be an effect 
modifier rather than a confounder, we introduced an interaction term for age 
 97 
rather than adjusting for age in the regression equations. An effect modifier is a 
factor that is associated with the outcome, but not with the exposure, and if 
present, the magnitude of the effect of the exposure on the outcome will vary 
depending on the level this third factor/effect modifier [156]. The results 
showed no differences for the effect of age, and it was kept as a confounding 
variable. 
In the EconCOPD study, possible predictors of productivity losses, AECOPD 
incidence, and costs, were included in the multiple regression models. It has 
previously been demonstrated that lower education, female gender, and higher 
age are associated with higher productivity losses and costs [173-175], and we 
adjusted for these covariates in our multivariate equations. 
In the paper on incidence of AECOPD, initial bivariate analyses were 
performed for each possible predictor, and those significant at a level of p<0.10 
were included in the final multivariate model. With this approach, precision of 
adjustment estimates is maximised [150]. Additionally, the magnitude of 
associations was evaluated by presenting the results from several models with 
differing combinations of adjustment variables. Some variables that were not 
available, and hence not adjusted for, come to mind while wrapping up this 
thesis during the pandemic. Factors such as hygiene or frequency of hand 
washing, social contacts or having children around exposing the participants to 
a variety of viruses, would be interesting to investigate in relation to AECOPD. 
Additionally, one could imagine that other factors such as physical activity or 
participating in pulmonary rehabilitation, nutrition, or seasonality also could 
affect the rate of exacerbations. 
In both data sets, there might have been some unidentified factors that 
confounded the results. Even so, we are quite certain that we have included the 
most important possible confounders, and that further adjustment would not 
alter the results significantly. Further adjustment would also increase the risk of 
overadjustment and bias toward the null [176]. 
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5.1.3 Statistical considerations 
Paper I on unemployment in the BOLD study, had a dichotomous outcome. 
Traditionally such outcomes have been studied with logistic regression. Lately, 
though, sophisticated statistical methods have made it possible to use other 
regression equations even for categorical outcomes. We used a generalized 
linear model (GLM) with multilevel mixed-effects. In more traditional, simpler 
models, interactions between variables and nested structure in the data would 
be ignored. Multilevel models allow for a more complex construction of 
regression equations in such a manner that the reciprocal influence between 
individuals and society is recognized, and the analyses of the phenomena 
become more correct [177]. Alternatively, we could have used a fixed-effect 
model. In a fixed-effect model, the sites included would have been treated 
more exclusively, whereas in the mixed-effect model we used, the sites are 
treated as a random sample of all possible sites. We believe that the sites in the 
BOLD study can represent a random sample of many sites across the world, 
and that it is better to treat them as such. 
 














In the EconCOPD study, we investigated three outcomes -productivity losses, 
incidence of AECOPD, and costs related to COPD and exacerbations. The 
distribution of all these outcomes was skewed. For the initial unadjusted 
analyses, we thus used Kruskal-Wallis test with ties. Additionally, in the paper 
on productivity losses we did a Spearman`s rho test for the correlations 
between days of lost productivity and age, FEV1 % of predicted, comorbidities, 
and exacerbations of respiratory symptoms. For the multivariate regression 
analyses, we performed median quantile regression that does not rely on the 
assumption of normality nor homoscedasticity, and hence suited our skewed 
outcomes [178]. A further advantage, is that the coefficients of median quantile 





Figure 7: Distribution of outcomes (incidence of exacerbations, productivity losses, and costs) in the 
EconCOPD study. Patients, cases, and controls included, N=418. 
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5.1.4 Health economic considerations 
The burden of disease, and how to measure this, is still a topic of debate. There 
are many aspects to include in a comprehensive appraisal of disease burden, 
and this complexity might be the origin of why there is no consensus on how to 
do this. Using descriptive cohorts, with no intervention and the availability of a 
control group, we chose to calculate the incremental costs. As an option, 
attributable costs can be calculated, but it has been seen that incremental, or so 
called excessive costs, are more accurate than attributable costs [101]. 
As the criticism of COI studies arose, some alternative approaches were 
developed to deal with the possible shortcomings of COI studies [179]. These 
include more sophisticated measures of change in health related to disease, like 
quality-adjusted life-years (QALYs), and the previously mentioned DALYs. 
Such measures both consider the change in quality of life and the change in 
quantity, i.e. the lower life expectancy associated with disease [97]. A further 
criticism has been that burden of disease studies, are of no value if not reported 
together with some kind of benefit or efficiency measurement [11]. I.e., there is 
a need of comparing the burden in a group with a given health care programme 
to the burden in a group without such a programme, or intervention, to enable 
decision makers to take informed choices. There are three main study types that 
consider the costs in relationship to a beneficiary outcome (or an aggravated 
outcome), namely cost-effectiveness analysis (CEA), cost-utility analysis 
(CUA), and cost-benefit analysis (CBA). 
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Cost-effectiveness analyses, are mostly used to estimate the effects of a limited 
range of treatment options to illustrate for decision makers the possible choices 
they can make within their budget [11]. The effectiveness measures can for 
instance be cases detected of a certain disease, exacerbation-free intervals of 
asthma or COPD, or years of life gained. Decision makers then have to make 
trade-offs when they decide upon which effect/intervention/treatment/screening 
to spend their limited resources on. Lately, cost-utility analyses have become 
more popular as the outcome often is measured in QALYs or DALYs that 
incorporate weighting of the various disease states that are investigated, 
enhancing comparability. In CUA, several different outcomes can be 
investigated together with a final combined outcome stating the costs per e.g. 
QALY gained, allowing for comparisons across any different health care 
programme [11].  
In contrast to CEA and CUA, CBA value the programme consequences in 
monetary units. With this approach, both the costs of a programme and the 
outcome of the programme, is given in the same monetary unit, making direct 
comparison of the expenditures to the gains possible. The difference between 
these two, is the net social benefit, be it negative or positive, clarifying if the 
programme is worthwhile or not [11]. All in all, comparing health care 
programmes, be it preventive programmes, or treatment alternatives, data on 
QALYs or DALYs combined with the effectiveness or benefit of the 
programme, give a comprehensive evaluation of the burden of disease and 
possible advantages that can be obtained from different choices in health care. 
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Both the BOLD study and the EconCOPD study were descriptive observational 
studies with no intervention. We did not have information in our data sets to 
make evaluations of the consequences of COPD on reduced quality of life or 
disability-adjustments. Such analyses could have provided valuable additional 
insight. From the EconCOPD dataset, we performed a comprehensive cost-of-
illness analysis on the data available in our descriptive cohort study, including 
both direct and indirect incremental costs of COPD in two different samples. 
The burden is given in monetary units, and can as such, be compared to similar 
COI studies on COPD, or on other diseases. 
We chose the human capital approach when assigning a monetary value to the 
lost productivity. The most used alternative way of assigning money value to 
reduced working capacity, is the friction cost method. As explained in the 
introduction, this method implies finding the time period when absenteeism 
from work leads to reduced productivity until someone from the pool of 
unemployed people start doing the chores of the one absent. In Norway, there 
has not been a high unemployment rate for many decades [180], and hence, if 
someone is sick or disabled to work, it can be viewed as a permanent loss of 
productivity. Additionally, the HCA value human beings independently of their 
capacity to participate in the work force. I would like to argue that this 
viewpoint is more ethical than a perspective where people have no value if not 
working for an income. 
With the intention of accomplishing a COI study that includes total costs to 
society, we have performed a detailed gathering of data. Albeit, there might be 
some costs missing to make it complete. Intangible costs are the costs related to 
pain and suffering both among patients and relatives, and are the ones most 
difficult to measure. We did not include intangible costs as we did not have the 
information in our dataset to do so, and this make our results on the burden of 
COPD even more conservative. 
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5.2 Discussion of the main results 
The paper from the BOLD study presented the burden of unemployment 
associated with CAO. The papers from the EconCOPD study, addressed the 
burden inflicted by COPD by productivity losses, acute exacerbations, and 
societal costs. Additionally, all three papers from the EconCOPD study 
examined the differences between a selected hospital sample and a general 
population sample. 
5.2.1 Unemployment and productivity losses 
At baseline in the BOLD study, the CAO subjects reported being unemployed 
in 19.6% (95% CI 18.0 – 21.4) of the cases, and having paid work in 36.7% 
(34.7 – 38-8) of the cases. The corresponding numbers for the non-CAO 
subjects was 16.2% (15.6 – 16.8) and 53.2% (52.4 – 53.9) for unemployment 
and paid work, respectively. There was no overlap of the confidence intervals, 
indicating significant differences, though unadjusted. After extensive 
adjustment and excluding participants above 65 years of age, we found a 43% 
overall increased risk of being unemployed for the CAO subjects compared 
with the non-CAO subjects (OR 1.43 (95% CI 1.14 – 1.79)). 
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In the EconCOPD study, 87% of the control subjects reported having a paid 
job, whilst 55% and 31% of the COPD cases and –patients had a paid job. The 
controls, cases and patients reported receiving a disability pension in 7%, 30% 
and 65% of the cases, respectively. In adjusted analyses, the COPD cases from 
the general population had an annual incremental productivity loss of 5.8 days 
(95% CI 1.4 – 10.1) compared to the controls, and the hospital recruited COPD 
patients had an annual incremental productivity loss of 330.6 days (327.8 – 
333.3) compared to controls. The rates of unemployment and paid work differ 
slightly in the BOLD Study and the EconCOPD Study. The rates given from 
the BOLD Study, include all participants at all sites, not only the participants 
from Bergen. Further, the wording of the question was not identical in the two 
studies. In the BOLD Study, the question read: “At any time in the past 12 
months, did you work for an income?”, with “yes” or “no” as possible 
alternatives. In the EconCOPD Study, the question was worded as follows: 
“What is your current work situation?”, with the options of ticking “paid work” 
(full time or part time), “disability pension”, “early retirement”, “student”, “age 
pension”, or “unemployed”. 
 105 
Few prior studies have investigated employment rates and productivity losses 
for COPD patients in general populations [112, 181-183], and even fewer have 
included spirometry for diagnosing airflow obstruction [112, 183]. Montes de 
Oca et al found the mean work life participation to be 41.8% amongst COPD 
patients versus 57.1% amongst controls in five Latin-American cities [183]. 
The proportion of employed participants in the global BOLD study was quite 
similar, though slightly lower. A possible explanation could be that the five 
sites included in the PLATINO study (Montevideo, São Paulo, Santiago, 
Caracas, and Mexico City) reflects a more homogeneous society than all the 
sites included in the BOLD study. In their adjusted analyses, COPD was not 
significantly associated with employment status in the developing countries 
included in the PLATINO study. When stratifying on income status of the 
participating sites in the BOLD study, we found a similar pattern. In most of 
the LMIC in the BOLD study (apart from Annaba, Cape Town, and Kashmir), 
having CAO was not significantly associated with unemployment. In the high-
income sites, though, there was a more persistent pattern of higher 
unemployment amongst CAO participants compared to non-CAO subjects. By 
stratifying on income status, we clearly see that a comparison across sites that 
differ to such an extent in economy, and by acquaintance also in culture and 
social welfare, is very intricate. An important source of origin to this pattern, 
might be the differing welfare systems in the BOLD sites. If disease does not 
entitle the inhabitants in a society to receive social security, one might suspect 
that many still have to force themselves to keep on working even when they 
feel disabled to do so. In high-income sites, however, the inhabitants have the 
privilege of counting on economic support when disease and disability reduce 
their working capacity, and may therefore be inclined to quitting work sooner. 
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In the OLIN study, Jansson et al found more sick leave amongst COPD 
patients with mild airflow obstruction, whilst all other GOLD-stages had more 
early retirement [112]. They did not report employment rates, and did not use a 
control group to estimate incremental productivity loss. But apart from these 
methodological issues, their approach was similar to ours. They had a 
population-based sample, used the HCA to calculate the costs of reduced 
productivity, and they calculated the direct costs in a bottom-up manner. 0.2% 
vs 15.2% were classified as early retirees amongst the mild vs very severe 
cases of COPD in Jansson`s study, and average annual number of days in sick-
leave ranged from 1.1 to 22.6 for the respective disease severities. Not 
surprisingly, we saw the same pattern of less sick leave with increasing COPD 
severity along with increasing use of disability pensions.   
Days of productivity losses for COPD patients were reported by Lou et al in a 
study from rural China [182]. They found a mean annual productivity loss of 
150 days per COPD patient, and that family members lost 59 days of work 
annually. The study was performed in a rural area with more than 50% 
illiteracy amongst the participants. All participants had COPD, but 96% had 
never heard about the diagnosis, and a third did not know that smoking was a 




There has been a repeated debate in Norwegian society about the welfare 
schemes and the ability to participate in the workforce during short- and long-
time sickness. In the 1970s, people with physical labour were not covered by 
the same schemes of full salary from the first day of sick leave as people with 
clerk jobs [184]. Parties on both the right and left wing of politics agreed that 
these schemes should be valid for all sorts of labour, it was “ideologically 
indisputable”, as Jo Benkow from the Norwegian Conservative Party 
(“Høyre”) stated it [184]. Even so, there has been repeated worries about work 
ethics amongst employees, and some argue that the welfare schemes are too 
permissive and easy to cash in on. Amongst adults aged 18-66 years, an 
increase in long-term sick leave from 2.5% to 3.0% was found for the years 
2005 to 2009 [185]. This was along with an increase in employment rates 
where Norway had an employment rate approximately 7% higher than in the 
European Union [184]. It has been thought that more people with sub-optimal 
health are employed when there are more jobs available, and hence, the 
likelihood of sick leave increases. Additionally, people who need long-time 
sick leave or disability pensions seem to be a group of severely ill people who 
in reality are not able to work due to their illness [185].  
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A pattern of overuse of sick leave or disability pensions amongst COPD cases 
with low grade of symptoms is not evident in our data. The COPD patients 
from the hospital register, are, as a group, severely ill and have more 
comorbidities than the COPD cases from the general population. 31% of the 
hospital COPD patients and 55% of the population COPD cases were still 
working at baseline. We found that COPD cases from the general population 
had an incremental productivity loss of 5.8 days per year compared to controls. 
For COPD patients from the hospital register, on the other hand, the 
corresponding number was 330.6 days per year. Not only does this show that 
people with a modest COPD intend to stay in the workforce. With such a 
massive difference, it is also obvious that the heavier the burden on the patients 
gets, the higher the need for sick leave and disability pension. It is of maximum 
importance, both with a patient perspective and with a socioeconomic 
perspective, to avoid the progression of the disease from mild stage to more 
grievous stages. 
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There has been a paucity of data on productivity losses and unemployment 
associated with COPD, and especially from general populations. Our results 
show that COPD is associated with a higher risk of reduced working capacity, 
both when it comes to sick leave and permanent disability/unemployment. It is 
not immediately straightforward to compare results across countries with 
differing economies, cultures, and welfare systems, and the differing methods 
used in the scarce studies available, make it even more complicated to compare 
our results to previous literature. Comparison to other disease groups is 
challenging using our results as the previous literature on productivity losses is 
scarce, but an interesting study by JM Kinge et al investigated both the 
economic losses and burden of several medical conditions in Norway [186]. 
They found diseases of the respiratory system to rank 7th amongst all medical 
conditions considered, both when measured in DALYs lost, and when using the 
HCA to calculate the productivity losses. Large disease groups like neoplasms, 
mental disorders, diseases of the circulatory system, and musculoskeletal 
system ranked higher. The economic loss due to respiratory diseases was 17.2 
billion NOK, more than 5% of the total economic loss due to all diseases in 
2013. 
5.2.1.1 Risk factors for unemployment and productivity losses 
Overall in the BOLD study, we found several factors increasing the risk of 
unemployment apart from CAO. Decreasing FVC, female sex, increasing age, 
lower education, and comorbidities were all significant risk factors for 
unemployment. When stratifying on income, some variation became apparent 
between the sites. The strongest predictors of unemployment in high-income 
sites were age, and lower education. In LMIC, the strongest predictors were 
female sex, and age. 
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In the OLIN study, predictors of reduced working capacity were not examined. 
Our results are in line with the findings in the PLATINO study where age, 
female sex, lower education, comorbidities, and also dyspnoea were associated 
with a higher risk of unemployment [183]. They adjusted for both dyspnoea 
and spirometric COPD in their main model, whilst we had no additional 
adjustment for severity of airflow obstruction, or respiratory symptoms in our 
main model. When we added respiratory symptoms, the association between 
CAO and unemployment was reduced (1.26 (1.00 – 1.57)). We believe that the 
respiratory symptoms that accompanies COPD are important when it comes to 
quality of life and ability to work, as seen by the reduction of the association. 
But there are probably other variables involved in this complex interaction, as 
the association continues to be statistically significant even after additional 
adjustment for respiratory symptoms. One can speculate on what these 
variables might be, though it was not further tested in our material. Other 
symptoms associated with COPD, like asthenia, might explain some of the 
association. A stratification on exacerbation frequency might also have 
elucidated further on this issue. 
5.2.2 Measures of incidence of acute exacerbations of COPD 
Table 5 shows the mean annual exacerbation rate per COPD patient from 
selected studies. Methodological differences and varying definitions of 
AECOPD make comparison across studies difficult. All studies listed in Table 
5 presented the mean annual exacerbation rate per COPD patient except the 
study by Wallace et al that gave the mean exacerbation rate per 100-person 
years. This was transformed to mean annual exacerbation rate per person by 
dividing by 100. 
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Table 5: An overview of studies on incidence of AECOPD. Incidence given as 
annual exacerbation rate per person.
* “Best study”; prospective cohort study with a large sample from several general populations. 
** Paper III of this thesis. 
 
With the objective of studying the distribution and frequency of AECOPD in a 
general population, and to optimise the external validity of study results, we 
consider prospective cohort studies with a large sample from a general 
population to provide the most reliable and valid results. In Table 5 these are 
marked with an asterisk (*), and only one study other than ours, satisfied these 
criteria [60]. Again, this study is from the PLATINO project, and sampled from 
general populations in five Latin-American countries. They used a symptom-
based definition of AECOPD, and exacerbations were self-reported for the year 
preceding the study. The mean annual exacerbation rate per COPD participant 
was 0.58, and when adding the need of visiting a doctor due to the worsening 




































































Our results are quite on par with the results from the much alike PLATINO 
study, though in 2009 they had not begun their follow-up, and the study by 
Montes de Oca might be best classified as cross-sectional (not prospective). 
The subsample of COPD cases from our general population had a mean annual 
exacerbation rate of 1.0 when defining AECOPD by symptoms. Crossing over 
to a resource-based definition, the same subsample had an average annual 
exacerbation rate of 0.4. Our study was prospective, and collected information 
from participants every 12 weeks minimising recall bias. Some studies have 
seen that events requiring medical assistance or hospitalisation, i.e. more severe 
events, are better remembered than smaller symptom alterations [162, 187]. 
This can be interpreted as a higher accuracy for the information gathered on 
resource use than symptoms, favouring utilisation over self-reported symptoms 
for studies on exacerbations. 
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Elucidating further on rate of exacerbations, we analysed the hospital sample 
with both exacerbation definitions as well. Not surprisingly, the mean annual 
exacerbation rate was 5.9 and 1.0 per person with the symptom- and resource-
based definitions, respectively, in this subsample. Seemungal et al, followed a 
small sample of 70 COPD patients attending an outpatient ward for 12 months 
[62]. With a symptom-based definition, they reported a mean annual 
exacerbation rate of 2.7 per participant, less than half of what we found. 
Donaldson et al also followed the same outpatient sample of COPD patients for 
a year as Seemungal et al, and defined exacerbations by symptoms [7]. The 
median exacerbation rate per COPD patient per year was 2.53. The average age 
in the sample used by Seemungal and Donaldson was close to the average of 
the participants in our hospital subsample. In the two mentioned studies 
though, only participants with an FEV1 < 70% of predicted were included, 
whilst we included participants with an FEV1 < 80% of predicted. One would 
expect the higher severity of airflow obstruction to result in higher 
exacerbation rates, not lower [60, 66, 68]. A possible explanation could be that 
in the studies by Seemungal and Donaldson, both utilising the same small 
sample, exacerbations were reported differently than in our study. They 
depended on the participants calling by telephone to study staff when 
experiencing a deterioration in symptoms, or noting their symptoms in diary 
cards. An aspect arising from these considerations, is whether AECOPD is 
adequately studied over one year, or if the low incidence suggests that the 







5.2.2.1 Risk factors for the incidence of AECOPD 
Increasing airflow limitation was associated with higher exacerbation risk in 
both subsamples, and with both exacerbation definitions. Progression of COPD 
is often reflected in a decline in lung function. With lower lung function, 
patients are more vulnerable for fluctuations, and minor changes in symptom 
burden may lead patients to change medication or to be admitted to hospital, 
hence fulfilling the definition of having an exacerbation. The finding is in 
accordance with previous literature [7, 60, 64, 66], and indicates that avoiding 
disease progression is essential both for patient wellbeing, and for the 
economic burden.  
Further, for both exacerbation definitions, receiving maintenance therapy for 
COPD was positively associated with higher exacerbation risk in both 
subsamples. The previous mentioned PLATINO study had the same finding for 
“any respiratory drug” [60], and Husebø et al found that the use of ICS was 
associated with a higher exacerbation risk [64]. Other studies have found a 
protective effect of respiratory maintenance therapy on the risk of experiencing 
an exacerbation [151, 188, 189], and this is the main reason for recommending 
maintenance therapy in stable COPD [3]. We interpret our finding as an 
expression of disease severity, where patients with more frequent exacerbations 
have received ICS therapy, which is only partially effective in reducing these 
incidents. 
For the resource-based definition, female sex was associated with increased 
risk of AECOPD (IRR 1.57 (95% CI 1.15 – 2.14), but this was not the case for 
the symptom-based definition where gender was not significantly associated 
with the outcome. Montes de Oca et al found an association between female 
sex and exacerbation risk in bivariate analyses, but this association became 
insignificant in multivariate analyses [60]. In the multivariate analyses by 
Husebø et al, female sex was, equally to our results, associated with increased 
risk of exacerbating [64].  
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Some observations indicate that women report more symptoms and utilise the 
health care system more frequently than men [190], but the explanation behind 
this seems very complex. It has been seen in several earlier studies that women 
experience more symptoms from COPD [191-193], and might seek medical 
advice earlier or more often as a consequence. Though it is not clear whether 
the explanation to the gender differences is biological, or cultural, a female 
phenotype has been proposed. Increased inflammatory response in females, 
higher susceptibility to tobacco, and the protective effect of oestrogens 
premenopause are postulated mechanisms that might be responsible for the 
gender differences in COPD [194-197]. Some have seen that physician`s 
responses to a patient complaint differs if the patient is male or female, 
resulting in less use of spirometry amongst women, more underdiagnosis in 
women, and less referral of women to specialists [142, 198, 199], constituting a 
cultural or societal explanation to the phenomenon. A possible interpretation of 
our result is that women have more severe exacerbations needing medical aid, 
as female sex only was associated with the risk of resource-defined 
exacerbations, not symptom-defined ones. Kilic et al found proof of this in 
their study performed in Ankara [200]. On the other hand, it was found by de 
Torres et al that men had significantly higher all-cause and respiratory 
mortality compared to BODE- and FEV1-matched women [201]. A perception 
might be that how women seek medical aid is more appropriate than the 
tendency among men, reflected by these lower mortality rates. Comparison 
between different cultures and countries is also complicated, as gender 
differences vary immensely.  
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With the symptom-based definition of AECOPD, both age and receiving 
influenza vaccination were associated with a significantly reduced risk of 
exacerbation. Other studies have shown that increasing age is associated with a 
higher exacerbation risk [64, 66], but our finding was the opposite. One could 
speculate that elderly people do not like to complaint, and are taught to tolerate 
quite a lot from their childhood during the second world war or during 
economic hardship which was more normal in Norway before the petroleum 
era. The reduced risk of exacerbation associated with the influenza vaccine is 
in accordance with previous studies [202], supporting continuous use. 
 
5.2.2.2 Effect of exacerbation definition 
In both subsamples of COPD participants, the risk of AECOPD was higher 
with the symptom-based definition compared to the resource-based definition. 
In Table 5, in line with our findings, the studies listed with a symptom 
definition are the ones with the highest exacerbation rate [7, 62, 64]. There is 
one exception though: the general population cohort study by Montes de Oca et 
al [60] that used a symptom-based definition of AECOPD but giving a low 
annual exacerbation rate at 0.58/COPD patient. The most likely explanation is 
that this study was performed in a general population, and not on selected 
hospital or outpatient samples. Additionally, the study participants were asked 
for worsening of respiratory symptoms during the year prior to the study, 
which might have introduced some degree of recall bias. 
The basis for the difference seen between the two exacerbation definitions is 
most likely that symptoms are actually the reason for contact with the health 
care system. And only a fraction of symptom events will be perceived by the 
patients as “important enough” to elicit health care utilisation. Furthermore, 
symptoms are of subjective origin, whilst resource-use is a more objective 
decision made by persons apart from the COPD patient. It takes more to get to 
the point of resource-use, than it takes to make a subjective complaint. 
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Suzuki et al carried out an interesting study in Sapporo, Japan, where they 
implemented several different exacerbation definitions [65]. They found a 
decreasing exacerbation rate with increasing criteria added to a symptom-based 
definition (criteria added were prescription change, antibiotic treatment, and 
hospital admission). Our results combined with previous knowledge endorse 
the realisation of studies on AECOPD with a resource-based definition for 
more accurate estimates. If other definitions are used, the researchers should 
specify the differences expected in the results due to the chosen definition. 
 
5.2.3 Cost estimates for COPD and acute exacerbations of COPD 
It is difficult to compare our results to earlier studies due to differing 
methodology. To the best of our knowledge, no other study has estimated the 
incremental costs of COPD exacerbations with multivariate regression analysis 
in a general population. 
Table 6 summarises some important, previous studies on COPD costs and 
exacerbation costs. Cost estimates form the OLIN study in Northern Sweden 
have reported mean annual COPD costs according to GOLD-stage (Jansson et 
al) [112], and exacerbation costs of prior exacerbations in a top-down manner 








Table 6: An overview of studies on costs of COPD and costs of AECOPD as of 
April 2021. Costs given in Euros for comparability. 
 
Costs calculated into Euros based on the exchange rate for the year of publication (applies to the 
studies by Andersson and AbuDagga). 
*Studies that present costs per exacerbation 
§ “Best studies”: Randomly sampled, prospective cohort studies from a general population. 
^Paper IV of this thesis. NS: non-significant. 
Both direct and indirect costs of COPD were reported by Jansson et al [112]. 
As visualised in Table 6, our mean costs (for all GOLD-stages together) lie in 
the interval of costs reported for the separate GOLD-stages in Janssons study, 
though in the higher end of the interval both for the direct and indirect costs. 
We have reported mean costs per COPD participant, whilst in the OLIN study 
they stratified on GOLD-stage. In total, we speculate that our average 
resembles the expected mean from the OLIN study, though the total mean was 
not given by Jansson et al. 
































































Jansson et al used a bottom-up approach to calculate the mean annual costs per 
COPD patient according to GOLD-stage. They had a general population 
sample that was prospectively followed and interviewed four times quarterly 
by telephone, the study design that EconCOPD was based on. The unit costs 
they used for calculation of the direct costs, included visits to GPs, primary 
care personnel, specialists, other hospital personnel, and emergency rooms. 
Further on, they also included costs per radiology exam, per day spent admitted 
to hospital (both to “regular” wards, and to intensive care units), costs for 
drugs, and oxygen therapy. Our direct costs were calculated using the same 
units apart from radiology exams, though we additionally had information on 
physiotherapy costs, home nursing, and rehabilitation programmes. For the 
indirect costs in the OLIN-study, they used the same HCA as we did, and 
calculated the days of lost productivity according to each participant`s average 
monthly salary. We calculated the productivity losses according to the average 
salary by sex, age, and education given by Statistics Norway. We did not have 
information on each individual`s salary. Overall, the final study design was 
very much alike that of the OLIN study, though we did include some additional 
unit costs. In OLIN, they reported the cost per GOLD-stage, whilst we 
estimated the mean cost per COPD patient/case independent of GOLD-stage. 
As speculated, if they were to give a general mean cost for all GOLD-stages, it 
seems that this mean would have been not so far from our estimated mean, 
though maybe a bit lower. We did include several cost items more, which may 
explain the speculated difference. 
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Other studies on COPD costs include those by Lisspers et al [203], and 
Rehman et al [204]. Lisspers et al used data registries from primary care 
centres across Sweden to retrospectively study direct and indirect costs 
associated with COPD and both moderate and severe AECOPD. Costs were 
compared to age- and sex-matched controls. It is difficult to compare our 
results to those of the study by Lisspers et al as they report costs per age-group, 
and stratified by frequent and non-frequent exacerbator phenotypes. They do 
present the total direct costs per COPD patient per year (€13,179 vs €2,716 per 
matched control). This is higher than what we found for the mean annual direct 
cost per population-based COPD case and per hospital-recruited COPD patient 
(€3,829 and €9,504, respectively). We could convert our results to 2018-€ by 
using the consumer price index-calculator of Statistics Norway to give our 
results in 2018-NOK. Then, with the exchange rate of 2018 (1€ = 9.94NOK), 
our results convert to €3,992 and €9,909 for the cases and the patients, 
respectively. There are some essential differences in design and data collection 
between our study at that of Lisspers et al that might explain the differences 
seen, i.e. prospective vs retrospective design, general population vs primary 
care, and they did not include home nursing services, physiotherapy, ER visits, 
oxygen therapy or rehabilitation programmes. 
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The systematic review performed by Rehman et al [204] included several 
European countries, and found substantial differences in the direct and indirect 
costs between the countries. The article they included from Norway [205] had 
the highest direct costs per patient per year (€10,701), but it seems the authors 
misinterpreted this article. They have not given the incremental direct costs for 
Norway, but presented the total health-related cost when having COPD. Spain 
had the lowest direct costs (€1,715). This review was published before our 
fourth paper, and they had no Norwegian study on indirect costs included. The 
indirect costs were divided into sick leave and early retirement. The costs 
associated with sick leave varied from €998 in Greece, to €5,735 in Germany. 
The costs of early retirement ranged from €3,695 in Sweden, to €19,031 in 
Germany. The indirect costs exceeded the direct costs in all countries who 
reported on both costs. In accordance with our arguments, Rehman et al 
consider the social security policies to be the main cause behind the differences 
in indirect costs. Additionally, they included studies with both HCA and FCM, 
and applying both bottom-up or top-down methods in their calculations of 
costs, which makes comparison difficult. The indirect costs presented from our 
fourth paper in Table 6, includes both sick leave and early retirement/disability 
pension. Our results lie in the interval found by Rehman et al for the separate 
European countries. 
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When it comes to the costs associated with exacerbations of COPD, there are 
no previous studies that have investigated this in a manner similar to ours. 
Unfortunately, no multivariate analysis was made to evaluate the exacerbation 
costs neither in the OLIN study[110], nor in the studies by Miravitlles et al 
[109], AbuDagga et al [108], nor Lisspers et al [203]. Further on, we have not 
found any published study concerning indirect costs of exacerbations. Anyhow, 
there is one observation that seems clear from the results of these studies –the 
costs of exacerbations increase with severity of the event, and also by severity 
of COPD. Both in our study and in AbuDagga`s study, the severe 
exacerbations were approximately 50 times more expensive than the moderate 
exacerbations. 
 
5.2.3.1 Cost drivers 
The total societal health-related costs when having COPD, were €26,518 and 
€15,021 per person per year, for the hospital-recruited and population-based 
COPD participants respectively. The corresponding annual cost per control 
subject, was €6,740. The incremental direct cost for the population COPD 
cases was €490 in GOLD-stage II, and €1,938 in GOLD-stage III-IV. For the 
hospital-recruited COPD patients, the incremental direct cost was €2,252, 
€3,221, and €5,684 for GOLD-stages II, III, and IV, respectively. The 
incremental indirect cost was non-significant for the population cases in 
GOLD-stage II, and €46,215 in GOLD-stages III-IV. For the hospital-recruited 
COPD patients, the incremental indirect cost was €28,845, €29,570, and 
€48,338 for GOLD-stages II, III, and IV, respectively. 
 123 
For the population-based COPD cases, increasing GOLD-stage, exacerbations, 
comorbidities, and female sex, were all associated with higher direct costs. 
Some previous studies have shown a similar pattern of increased healthcare 
utilisation amongst women [174, 175], gender differences at equal or lower 
levels of smoking exposure [206], and as mentioned earlier in this thesis –a 
higher level of dyspnoea [193]. Kilic et al found that when women experienced 
severe exacerbations, the time till admission was longer than for men [200]. 
These are all possible mechanisms for higher costs amongst women. Both 
avoiding exacerbations and treating comorbidities have the potential of 
minimizing the direct costs in populations-based COPD cases. The indirect 
costs were significantly driven by GOLD-stage III and IV, but when adding 
adjustment for exacerbations this association lost its significance completely. 
GOLD-stage II was not significantly associated with increased indirect costs in 
the sample of population-based COPD cases. These findings might indicate 
that when FEV1 has fallen below 50%, workforce participation is difficult in 
the stable state of the disease, and the contribution by exacerbations on top of 
this is modest. Decision makers could learn from this finding. Treatment and 
initiatives that prevent the progression of COPD into more severe disease 
stages could be proven economically beneficial. 
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 Amongst the hospital-recruited COPD patients, exacerbations explained 27%, 
40%, and 48% of the direct costs associated with GOLD-stage II, III, and IV, 
respectively. Comorbidities were also significant drivers of direct costs in this 
subgroup. The only significant driver of indirect costs in this subgroup of 
hospital-recruited patients, was increasing GOLD-stage. This implies that 
exacerbations are of great importance when it comes to treatment-related costs 
in this subgroup. But for the costs of productivity losses, exacerbations do not 
play an important role. The interpretation of this finding is interesting, and we 
think that the prevention of reaching this stage of severity is crucial both when 
it comes to reducing indirect costs, and for the patient`s wellbeing. At this point 
of the disease, many are receiving long-term disability pensions, and will not 
be able to return to work in the future. In other words, avoiding exacerbations 
will undoubtedly reduce the treatment-related costs in this subgroup, but the 
indirect costs they inflict on society are permanent at this stage of the disease. 
Guideline treatment and awareness of the comorbidities associated with COPD 
has the potential of further reducing the costs. 
Dwelling a bit more on the costs associated with exacerbations, there seems to 
be a profound difference between the population-based and the hospital-
recruited participants. The exacerbations explained a substantial part of the 
direct costs, but none of the indirect costs, of the hospital patients. On the 
contrary, for the population-based COPD cases, moderate exacerbations 
explained all the indirect costs associated with GOLD-stage III-IV, but only 6-
13% of the direct costs. Nevertheless, the key finding is that in both groups, 
prevention of exacerbations could lead to reduced costs. These effects, though, 
will be visible in different parts of the national budgets. For the hospital 
patients, exacerbations are important to avoid to reduce the direct costs. But for 
the population cases, the exacerbations are more important to avoid if one 
wishes to reduce the costs associated with productivity loss. 
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5.2.4 Effect of sample source 
In paper II, III, and IV, we compared the results for the population-based 
COPD cases to that of the hospital-recruited COPD patients. In all 
comparisons, the hospital-recruited COPD patients had a higher burden and 
inflicted higher costs than the population-based cases. This is not a surprising 
finding, but the actual difference between the two samples was surprising. The 
productivity losses, the rate of AECOPD, and the total costs for the hospital 
COPD patients were, respectively, 57 times, 2-2.5 times, and 2 times higher 
than for the population-based cases. For instance, belonging to the hospital 
sample was associated with 59% - 78% increased risk of exacerbation 
compared to the population sample. With such tremendous differences, it is 
obvious that sample source is of great importance when designing studies on 
COPD. In epidemiology, the ability to generalize results with high external 
validity, is of essential value. The source of sampling should be general 
populations as far as possible, and if using selected outpatient or hospital 
samples, the expected deviations in results should be pointed out by the 
authors. In addition, we would like to argue that pharmaceutical companies 
who frequently visit GPs to present the effects of various inhalation drugs, 
should specify that the majority of their studies are based on selected samples. 
Hence, the GPs should be informed that the expected effect are not valid for 








6 Main conclusions 
1. 36.7% of individuals with chronic airflow obstruction had paid work the 
preceding year, whilst individuals without CAO had paid work in 53.2% 
of the cases. Chronic airflow obstruction was associated with a 43% 
higher risk of unemployment across the world in adjusted analyses. The 
association was strongest in high income countries. In low-to-middle 
income countries, female sex and increasing age were the strongest 
predictors of unemployment. 
2. COPD cases from a general population had a mean annual incremental 
productivity loss of 5.8 days compared to controls. COPD patients 
recruited from a hospital register had a corresponding incremental 
productivity loss of 330.6 days compared to controls. Female sex and 
lower education were predictors of a higher productivity loss in both 
subsamples. 
3. COPD cases from a general population experienced 0.4 mean annual 
resource-defined exacerbations of COPD, and 2.9 mean annual 
symptom-defined exacerbations of COPD. COPD patients from the 
hospital register experienced 1.0 mean annual resource-defined 
exacerbations of COPD, and 5.9 mean annual symptom-defined 
exacerbations of COPD. Increasing GOLD-stage was associated with an 
increasing rate of AECOPD in both subsamples. 
4. Belonging to the hospital sample was associated with a significantly 
increased risk of experiencing an AECOPD compared to the general 
population sample. The risk was 59% increased with the resource-based 
definition of an AECOPD, and 78% increased with the symptom-based 
definition. 
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5. The average annual total costs for a COPD patient from the hospital 
sample was almost twice as high as for a COPD case from a general 
population (€26,518 vs €15,021). Compared to control subjects, COPD 
patients from the hospital register incurred nearly four times the costs. 
The costs related to reduced productivity were significantly higher than 
the treatment-related costs in both sampling sources. 
6. Severe exacerbations were significant cost drivers of treatment-related 
incremental costs in both hospital-recruited patients and population-
based cases. Moderate exacerbations explained all the incremental costs 
associated with the productivity losses in the population-based COPD 
cases, but none of the incremental costs associated with the productivity 
losses amongst the hospital COPD patients. 
7. Increasing GOLD-stage, female sex, and comorbidities were 
significantly associated with incremental treatment-related COPD costs 
in the population-based sample. For the costs associated with 
productivity losses in this group, GOLD-stage II did not drive the costs. 
GOLD-stage III-IV was a significant cost driver before adjusting for 
exacerbations, but lost its significance after adjusting for moderate 
exacerbations. Amongst the hospital-recruited COPD patients, 
increasing GOLD-stage, severe exacerbations, and comorbidities were 
cost drivers of the treatment-related incremental costs. The costs of 
productivity losses in this group was driven by increasing GOLD-stage. 
Exacerbations did not affect the costs of productivity losses at this stage 
of the disease. 
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8. All three papers originating from the EconCOPD Study demonstrated 
significantly higher burden of COPD in the hospital-recruited sample 
compared to the population-based sample. Days of lost productivity per 
year was 57 times higher, the rate of AECOPD was 2-2.5 times higher 
(depending on exacerbation definition), and the costs were nearly 2 


















7 Implications and future perspectives 
This thesis describes the burden of COPD in unemployment and loss of 
working capacity, rate and risk of experiencing exacerbations, and societal 
costs. Further, we have detected the most important predictors of the burden 
measured in these outcomes. As stated by Chapman et al in the European 
Respiratory Journal: “Estimates of the components of the overall healthcare 
costs of a disease can help decision makers target interventions where they may 
have the most impact on overall disease-related healthcare costs because the 
component is a driver of the overall burden of the disease” [207]. We agree 
with this statement, and would like to append that sample source is of vital 
importance when performing cost-of-illness studies on COPD. Our papers 
show that not all populations are comparable, and not all choices made in the 
design of studies serve for comparison between studies. We argue that general 
populations should be the gold standard for cost-of-illness studies with the aims 
of achieving high external validity and to be of informative assistance for 
decision-makers. If a general population sample is not achievable, the authors 
should inform on the expected increased burden found in selected populations. 
Further, we recommend a bottom-up approach for the direct cost calculations, 
and in countries with low unemployment rates and mainly public health care, 
we recommend the HCA over the FCM or WTP. 
The rate of exacerbations has been studied to quite an extent so far, and further 
studies on this topic might not be necessary. The findings of consistent 
increased burden in the hospital sample compared to the population sample 
though, have not been investigated previously. There is little doubt that these 
findings are reproducible, however it would be informative to examine this in 
other samples or other countries. 
 130 
While exacerbation rate, and predictors of AECOPD, seem to have been fairly 
well studied, the approach we used to investigate incremental costs of 
AECOPD has not been applied previously. Fitting several multivariate 
regression models to elucidate on cost drivers, including moderate and severe 
exacerbations, revealed information not seen before. With this approach, we 
have given detailed estimates of which costs for which subgroups of COPD 
patients that are affected by exacerbations, and which are not. These findings 
need to be confirmed in future research. 
Our findings in the BOLD study became even more interesting when 
stratifying the sites into high and low-to-middle income sites. CAO was 
consistently associated with higher risk of unemployment in the high-income 
sites, while it was not significantly associated with risk of unemployment in 
many LMIC. Rather, in these countries, female sex was the strongest predictor 
of unemployment. In high-income countries, lower education was, along with 
increasing age, a strong predictor of unemployment. This demonstrates where 
change is needed and where authorities should put their emphasis when aiming 
for minimizing inequity in working participation. 
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The role of female sex, or maybe one should say female gender as more of a 
cultural entity, might deserve some further investigation. Our findings associate 
female sex to higher productivity loss, higher rate of AECOPD, and higher 
costs. Some of these associations have been seen previously, especially the 
association to dyspnoea and exacerbation risk have been described in various 
studies [193, 195, 200]. The explanation behind this, however, is not 
completely understood. It seems to be of complex aetiology where both 
biology, genetics, and cultural or societal factors may play a role. While 
intervention based on sex is neither desirable nor ethical, further 
comprehension of the aetiology behind these issues may display some 
components to which change may serve as a relief on female burden of the 
disease. Perhaps, a longitudinal study incorporating early life events, 
childhood, and adulthood, with comprehensive data on heredity, demographic 
variables, lifestyle, occupational and leisure exposures, symptoms and 
extensive lung function testing could give further insight into this complex 
issue. 
The studies used in this thesis were of observational origin, with no 
intervention. When it comes to productivity losses and costs, there seems to be 
a cut-off around GOLD-stage III. Before this stage, there is less permanent 
disability, and haltering the progression of the disease at GOLD-stage II could 
prevent people from falling out of the workforce. When less than 
approximately 50% of lung function is left, there is more use of permanent 
disability pensions, and people do not easily recover the ability to work. 
Prevention of disease progression is essential to maintain working capability. 
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It would be interesting to explore possible benefits of an intervention not yet 
sufficiently investigated –i.e. pulmonary rehabilitation. In a cost-benefit-
analysis, pulmonary rehabilitation could be examined in two randomized 
groups of participants to explore possible effects upon quality of life, costs, 
exacerbations, and mortality. One study arm could supply regular treatment, 
and the other arm pulmonary rehabilitation in addition to regular treatment. 
Valuing the outcomes in a monetary unit, would enable the calculation of the 
net social benefit of such a programme. An approach like this could help 
decision makers target their interventions where they possibly would be of 
highest benefit, and would clarify if pulmonary rehabilitation could reduce the 
burden on the patients. 
All in all, we have demonstrated some important disease-related features giving 
rise to higher burden and costs. Decision makers may take advantage of these 
findings to alleviate both patient and societal burden of COPD. Future research 
including cost-benefit-analyses may show where to target intervention to have 












1. In paper I, the third sentence under Design (in the Methods 
section), should have said “The latter was defined by an increase in 
two major symptoms (dyspnoea, sputum volume, or sputum 
colour), or one major and one minor symptom (cough, sore throat, 
nasal secretion, wheezing, or asthenia) for at least two consecutive 
days (modified Anthonisen criteria). 
 
2. In paper III, Table 1 is correct, but in the text describing unadjusted 
comparisons between the groups, it should not say that smoking 
status (along with sex) had a similar distribution. Both pack years 
smoked and smoking status were significantly different in the three 
subgroups (p<0.001, and p<0.012 respectively).  
 
3. The original manuscript sent to the committee, had wrong 
numbering of a figure in the plain text of the dissertation on page 
51 (the actual figures had correct numbering). On page 51 it said: 
“Figure 3 shows the details of the inclusion and causes of non-
response for the whole study period”. –corrected to “Figure 4 
shows the details of the inclusion and causes of non-response for 
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ONLINE SUPPLEMENT MATERIAL  
METHODS  
The current report includes participants from 26 sites: Guangzhou (China), Manila 
(Philippines), Mumbai (India) Nampicuan Talugtug (Philippines), Pune (India), Kashmir 
(India), Annaba (Algeria), Cape-Town (South Africa), Fes (Morocco), Ife (Nigeria), Sousse 
(Tunisia), Adana (Turkey), Krakow (Poland), Lisbon (Portugal), Tartu (Estonia), Tirana 
(Albania), Bergen (Norway), Hannover (Germany), London (United Kingdom), Maastricht 
(The Netherlands), Reykjavik (Iceland), Salzburg (Austria), Uppsala (Sweden), Lexington 
(USA), Sydney (Australia), and Vancouver (Canada).  
Dyspnea was defined using the modified Medical Research Council questions with the 
following categories: only breathless with strenuous exercise (grade 0); short of breath when 
hurrying on the level or walking up a slight hill (grade 1); walk slower than people of own 
age or have to stop for breath when walking on own pace at level ground (grade 2); stop for 
breath after 100 m or a few minutes on the level (grade 3) and too breathless to leave the 
house or breathless when dressing or undressing (grade 4).  
Multivariable analyses for the pooled data-set were conducted using multilevel mixed-effects 
generalized linear model (meglm in Stata), assuming unstructured covariance matrix with a 
binomial distribution and a logit link function, with study site included as random effect and 
with estimations of odds ratios for unemployment.  
Comorbidities included in model 3 were hypertension, heart disease, diabetes, stroke and lung 
cancer. Respiratory symptoms included in model 5 were modified MRC dyspnea, wheezing 
and dyspnea, and chronic bronchitis symptoms) in addition to the Model 4 covariates.  
The individual participant data meta-analyses were performed using ipdmetan in Stata, with 
binomial distribution, logit link function and robust variance estimates. The I2 statistic (range 
0-100%) was reported to display the percentage of total variation across sites which was due 
to true site-by-site heterogeneity. I² is defined as 100% x (Q-df)/Q, with Q being the classical 
measure of heterogeneity (Cochran’s Q). I² is a simple and easily interpretable expression of 
site differences. Zero% indicates no observed heterogeneity (beyond what would be expected 
by  
chance), while <25%, 25 - 50% and > 75% is characterised as low, moderate and high 


































 Unit costs for hospital admissions were estimated using the accounts of Norwegian hospitals 
reported to Statistics Norway. Costs per day admitted in hospital are reported for diagnosis reported 
groups (DRG)-generating activity in hospitals, excluding capital costs.  
 The source of unit costs for visits to general practitioners (GP), emergency room (ER) visits, 
specialist physicians and physiotherapists were claims for year 2006 to The Norwegian Labour and 
Welfare Organisation and The Norwegian Directorate of Labour and Welfare. They administrate all 
claims for the Norwegian national health insurance. Co-payments were included. 
 Costs for visits at outpatient clinics were gathered from the Directorate for Health and Social 
Affairs. The estimates are based on data from 14 hospitals. Capital costs are not included. 
 Costs for home nursing services were based on estimates from the accounts of the city of 
Bergen in Western Norway. National estimates were not available. The cost of house aid is covered by 
the patients themselves, so we have used the participants’ information concerning co-payment.  
 Costs for home oxygen treatment and participation in a pulmonary rehabilitation programme 
were gathered from the accounts of Haukeland University Hospital in Bergen, Western Norway. Unit 
costs for physiotherapist-led training for COPD-patients were based on official prices (co-payments 
and claims) for physiotherapists receiving financial support from the Norwegian government.  
 Costs per defined daily dose (DDD) of prescription medication were gathered from the 
Norwegian Pharmacy Association (NPA). NPA provided a list of all approved drugs and the maximum 
prize set by the Norwegian Medicines Agency.  Over-the-counter (OTC) drugs were gathered from 
Farmastat AS who survey sales numbers from the pharmaceutical industry in Norway. All treatment-









	 at	home	 1	visit	 91	
	 at	office	 1	visit	 34	
ER	visits,	all	causes	 	 	
	 at	home	 1	visit	 82	


























Indirect costs – days of lost productivity Unit Cost (Euros) 
Male, age 40 – 50 yrs, primary education 1 day 119.3 
Male, age 40 – 50 yrs, secondary education 1 day 136.2 
Male, age 40 – 50 yrs, university education 1 day 186.7 
Male, age 50 – 60 yrs, primary education 1 day 117.2 
Male, age 50 - 60 yrs, secondary education 1 day 135.8 
Male, age 50 – 60 yrs, university education 1 day 183.0 
Male, age >= 60 yrs, primary education 1 day 112.2 
Male, age >= 60 yrs, secondary education 1 day 132.9 
Male, age >= 60 yrs, university education 1 day 181.0 
Female, age 40 – 50 yrs, primary education 1 day 101.4 
Female, age 40 – 50 yrs, secondary education 1 day 111.8 
Female, age 40 – 50 yrs, university education 1 day 141.2 
Female, age 50 – 60 yrs, primary education 1 day 100.6 
Female, age 50 – 60 yrs, secondary education 1 day 109.3 
Female, age 50 – 60 yrs, university education 1 day 138.3 
Female, age >= 60 yrs, primary education 1 day 99.0 
Female, age >= 60 yrs, secondary education 1 day 108.1 





e-Table 2; Characteristics of hospital- and population-recruited COPD cases and population-recruited 











N 102 53 107  
Male, N (%) 57 (56%) 30 (57%) 54 (50%) 0.662 
Age, mean (SD) 59.1 (5.2) 57.6 (6.2) 53.1 (6.9) 0.017 
Smoking status 









    Former smoker, N (%) 61 (60%) 22 (42%) 50 (47%)  
Packyears, mean (SD) 29.8 (21.8) 28.6 (17.7) 15.9 (11.9) <0.001 
Educational level 









    Secondary, N (%) 54 (53%) 19 (36%) 48 (45%)  
    University, N (%) 12 (12%) 12 (23%) 39 (36%)  
FEV1 % predicted 









    ≥50%, <80%, N (%) 51 (50%) 47 (89%)   
    ≥30%, <50%, N (%) 28 (27%) 4 (7%)   
    <30%, N (%) 23 (23%) 2 (4%)   
Mean FEV1 % predicted (SD) 47.0 (18.0) 65.6 (12.6) 94.3 (8.3) <0.001 
Median FEV1 % predicted (iqr) 50.7 (29.7) 68.4 (13.3) 93.1 (10.1) <0.001 
Comorbid conditions 









    Median (iqr) 1 (2) 1 (1) 0 (1) 0.003 
Resource-defined exacerbations 









    Severe, mean (SD) 0.2 (0.6) 0.0 (0.0) 0.0 (0.0) <0.001 
Maintenance therapy, N (%) 79 (77%) 22 (42%) 1 (1%) <0.001 
Undergone vaccination, N (%)     
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    Influenza 65 (64%) 11 (21%) 7 (7%) <0.001 
    Pneumococcus 42 (41%) 3 (6%) 1 (1%) <0.001 
BMI (m/kg2), N (%) 









    Normal range 42 (41%) 20 (38%) 45 (42%) 0.869 
    Overweight 52 (51%) 30 (57%) 61 (57%) 0.646 
Oxygen therapy, N (%) 9 (9%) 0 0 0.001 
Employment status at baseline, N 
(%) 
   Paid job 
     
32 (31) 
     
29 (55) 
     
93 (87) 
<0.001 
    Retired 1 (1) 4 (8) 4 (4)  
    Disability pension 66 (65) 16 (30) 8 (7)  
    Other* 3 (3) 4 (8) 2 (2)  
COPD = chronic obstructive pulmonary disease. SD = standard deviation. FEV1 = forced expiratory volume in 




e-Table 3: Annual utilization of healthcare services and annual productivity loss according to participant 















Hospitalisation, all causes 
   Median no. of days (iqr) 











Hospitalisation, resp illness 
   Median no. of days (iqr) 











Health care provider visits 
   GP visits 
    Median no. of visits (iqr) 
    Total no. of visits in group 
  Emergency room visits 
    Median no. of visits (iqr) 
    Total no. of visits in group 
  Specialist visits 
    Median no. of visits (iqr) 
    Total no. of visits in group 
  Outpatient clinic  
    Median no. of visits (iqr) 
    Total no. of visits in group 
   Physiotherapy 
    Median no. of visits (iqr) 
































































No. of medicines used 











   Median no. medicines (iqr) 







No. of prescribed 
medicines for obstructive 
lung diseasesb 
   Median no. medicines (iqr) 
















training led by 
physiotherapist 
   Median no. sessions (iqr) 
















Pulmonary rehab progrc 
    Median participation (iqr) 













Long term oxygen treatmc 
   Median oxygen use (iqr) 













Home nursing services 
    Median no. of hours (iqr) 














   Median usage (iqr) 














  Sick leave 
     Median no. of days (iqr) 























     Any disabilityc, N (%) 
     Median no. of days (iqr) 
     Total no. of days in group 
Total productivity loss 
     Zero daysc, N (%) 
     365 daysc, N (%) 
     Median no. of days (iqr) 
































a Includes over-the-counter medication 
b Inhaled corticosteroids, inhaled anticholinergics, B2-agonists, aminophyllines, leukotriene modifiers 
c Variable coded as 0/1 for all participants. 
Iqr – interquartile range. SD – standard deviation. Trend tests for hospital patients > population-based cases > 






e-Table 4: Annual productivity loss according to participant status in the EconCOPD study when 
participants >67 years of age are excluded. 
 
a Variable coded as 0/1 for all participants. 












Test for trend 
Productivity loss 
  Sick leave 
     Median no. of days (iqr) 
     Total no. of days in group 
Disability pension 
     Any disabilitya, N (%) 
     Median no. of days (iqr) 
     Total no. of days in group 
Total productivity loss 
     Zero daysa, N (%) 
     365 daysa, N (%) 
     Median no. of days (iqr) 























































e-Table 5: Annual unadjusted costs per person by different indirect costs and according to participant 









Sick leave, mean, median 
(iqr) 
1543, 0 (693) 2369, 0 (415) 2037, 136 (1530) p = 0.028 
Disability pension, mean, 
median (iqr) 
26953, 36727 (40959) 11885, 0 (25335) 2583, 0 (0) p < 0.001 
Total productivity lossb, 
mean, median (iqr) 
34195, 44072 (44310) 17105, 1471 (43198) 5544, 798 (4067) p < 0.001 
 
** non-parametric median test. 
NA – not applicable. Iqr - interquartile range. 
a Healthcare professionals includes: general practitioners, specialist physicians in private practice, hospital 
physicians at outpatient clinics, emergency room visits, physiotherapists, home nursing services and house 
maid from the local healthcare authorities. 





e-Table 6: Cases and controls, coefficients of multivariate median regression. Basic model adjusting for 
COPD status, sex, age, per comorbid condition added, education, and packyears. Exacerbations model 
adjusts for all covariates in the basic models in addition to acute exacerbations of COPD. 
95% confidence intervals in brackets. FEV1 – Forced expiratory volume in 1 second. Packyear: The equivalent 
of smoking 20 cigarettes of tobacco daily for a year.  
  


























COPD, FEV1 < 























































































































N 213 213 160 160 
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e-Table 7: Patients and controls, coefficients of multivariate median regression. Basic model adjusting 
for COPD status, sex, age, per comorbid condition added, education, and packyears. Exacerbations 
model adjusts for all covariates in the basic models in addition to acute exacerbations of COPD. 
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95% confidence intervals in brackets. FEV1 – Forced expiratory volume in 1 second. Packyear: The equivalent 

















N 337 337 209 209 
 204 
Appendices 
Appendix A – The BOLD core questionnaire. 
 
  Country Code  _____ _____ _____   1 
 
  City Code _____ _____   2 
 
  ID _____ _____ _____ _____ _____ _____   3  
 
  Date: _____ _____/_____ _____/_____ _____ _____ _____   4-6 
  d d m m y y y y 
 
BOLD CORE QUESTIONNAIRE 




1. What is the participant’s sex? Male q 1 7 
  Female q 2 
 
2. What is your race?    ___ ___ ___  8 
 
3. What is your date of birth?  ____ ____/____ ____/____ ____ ____ ____ 9-11 
  d d m m y y y y 
 
4. How many years of schooling have you completed?  ___ ___ 12 
 
5. What is the highest level of schooling you have Primary School  q 1 13 
 completed? Middle School q 2 
  High School q 3 
  Some College (Trade/Professional/Community)  q 4 
   Four-Year College/University q 5 
  None q 6 
  Unknown q 7 
 
6. What is the highest level of schooling your father Primary School q 1 14 
 has completed? Middle School q 2 
  High School q 3 
  Some College (Trade/Professional/Community)  q 4 
  Four Year College/University q 5 
  None q 6 
  Unknown q 7 
 
Respiratory Symptoms and Disorders 
 
These questions pertain mainly to your chest.  Please answer yes or no if possible.  If you are in 




7. Do you usually cough when you don’t have a cold? Yes q 1 15 
  No q 2 
  [If yes, continue with Question 7A; If no, skip to Question 8] 
 
 7A. Are there months in which you cough on most days? Yes q 1 16 
    No q 2 











































Appendix C – EconCOPD questionnaires (The Norwegian Cost of COPD Questionnaire-baseline 
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